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Imaging comprehends a broad group of diagnostic techniques capable of providing, 
to an operator or to a physician, visual representations of the internal part of the 
organism. Imaging has the important aim to support the diagnostic process and the 
pharmacological and surgical therapy of important illnesses such as tumours, 
cardiovascular and autoimmune diseases, neurodegenerative and myelodysplastic 
syndromes, bone fractures and many others. 
The most important imaging techniques exploited daily in clinical exams and basic 
research are radiography (RX), computed tomography (CT), magnetic resonance 
imaging (MRI), ultrasound sonography (US), positron emission tomography (PET), 
single photon emission computed tomography (SPECT) and Optical Imaging (OI), 
which will be explained in detail in the following pages. 
Imaging can be classified into two different categories, morphological and anatomical 
techniques (CT, US, and MRI) and molecular imaging (SPECT, PET and OI).  
Morphological and anatomical techniques are characterized by high spatial resolution, 
but they are not able to give any information about fine changes at the tissue, cell or 
molecular level. These techniques provide images of the body which allow detecting 
coarse changes in a tissue such as a tumour. In particular, MRI images present a 
lower spatial resolution than those obtained with CT, but they show a higher contrast. 
Molecular Imaging (MI) techniques, instead, consists in the visualization, 
characterization and measurement of biological processes at the molecular and 
cellular level in humans and other living systems. However, SPECT and PET do not 
possess a great spatial resolution, while OI suffers from limited depth penetration.1,2 
Combining morphological/anatomical and molecular imaging modalities (for example, 
PET/CT and PET/ MRI technology), it is possible to obtain improved images of the 
pathophysiological changes at the early stage of many disease with a high resolution.3 
Moreover, MRI and US are the only imaging techniques tolerated by pregnant women 
or children, since they are particularly sensitive to ionizing radiations required by all 
the other imaging techniques. 
The various imaging techniques exploit the energy provided by a source and measure 





the energy coming from the source meets the target organ, part of this energy is 
reflected backward, part is refracted, and a part is absorbed by the target organ itself. 
The measurement of these interactions allows, after suitable computed 
transformations, the generation of an image of the target organ.1,2,4 (Table 1.1) 
 




















Optical imaging (OI) 





















Table 1.1. The most important imaging techniques currently applied in biomedical 




As stated above, imaging techniques are very powerful diagnostic tools, but 
sometimes, for the correct visualization of a certain body district, the natural contrast 
between different tissues (i.e. physiological and pathological ones) is not enough. In 
fact, a great number of CT, US and MRI exams are acquired taking advantage of 





agent. A contrast agent consists in a molecular media used to improve the spatial and 
temporal resolution of an image.  
Moreover, molecular imaging contrast agents are able to visualize, characterize and 
measure biological processes.5 
Usually, morphological anatomical techniques require high doses of CA (mg -  g) while 
molecular imaging techniques require very low loadings of probes (ng - μg).6  
Of course, different imaging techniques require specific and very different contrast 
agents suitable to enhance the physical phenomenon that the specific imaging 
modality exploits. In fact, contrast agents are chemical compounds with the highest 
molecular diversity, but the large part of them are metal complexes, since the great 
tunability of their inorganic and organic functionalities, the resulting compound shows 
interesting and important different  characteristics. However, all CAs must be 
biocompatible, present a fast elimination by the organism after the clinical exam and 
must not provide pharmacologic by-effects whatsoever to the patient.1,2  
The development of innovative CAs for the early diagnosis of life-threatening illnesses 
is a very active topic in the literature.  
The research in this field is focused on the design of innovative CAs for non-invasive 
imaging, with high affinity to the target organ, high contrast efficiency, optimal 
pharmacokinetic profile (i.e. good biodistribution, intracellular uptake and ability to 




A complex is a chemical compound in which a central atom, often a positively charged 
metal ion, is bound, coordinated, surrounded by ligands, usually neutral or negatively 
charged.  
Ligands, instead, are neutral or charged molecules able to bind (coordinate) a metal 
ion to form a complex which, usually, possesses very different properties compared 
to the native metal ion. The ligand, interacting with the metal ion, can in fact increase 





Each ligand in a complex has at least one lone pair which binds the central atom 
generating a coordinated dative covalent bond. 
If the complex is formed between the central atom and more than one binding site on 
the ligand it is defined as a “chelate”.  
The number of donor groups present in the ligand able to coordinate the metal is 
called denticity (κ), while the number of bonds between the metal and the ligand is 
called the coordination number (C.N.) of the complex. 
Chelates are fairly more stable than ordinary complexes (chelate effect) and if the 
ligand coordination sites are arranged in a macrocycle, the stability increases even 
more (macrocycle effect). This is due to the reduced mobility of the chelate imposed 
by preorganized structural constraint (such as an alkyl chain between two 
coordinating moieties or a macrocycle). In fact, a monodentate ligand can easily 
escape a complex having no more than its electrons that keep it anchored to the 
metal. In a chelating agent or in a macrocycle instead, if one coordinating moiety 
leaves the metal, all other coordinating groups and the ligand scaffold itself stay still 
bound to the metal.     
Group d and f metals are excellent Lewis acids, therefore they are able to establish 
coordinate covalent bonds with molecules or ions that can act as Lewis bases 
(amines, carboxylic acids, thiols, phosphines etc.).7 (Figure 1.1) 
 
 
Figure 1.1. Schematic representation of the complexation reaction. The term 
chelating agent figuratively recalls the claws of a crab (the ligand) grabbing a prey 
(the metal). Kf and Kd are respectively the formation and dissociation thermodynamic 





Ligands that are directly connected with the central ion constitute the sphere of 
internal coordination, while counterions, compensating the total charge of the system, 
and solvation molecules constitute the external coordination sphere.  
Moreover, in a metal chelate the optimal stability is obtained when the metal and the 
chelating ligand are arranged in 5-membered units. Usually six membered chelates 
are less stable, but still possessing, in some case, a reasonable high stability. Rings 
with less than five members and more than six generally result in unstable 
complexes.7 (Figure 1.2) 
 
 
Figure 1.2. Stability of the metal complex as a function of the length of the chain 
between two donor groups.7 
 
Chelating agents are employed today for a large array of applications where an 
efficient coordination of a metal ion is required.  
These applications include pulp and paper manufacturing and food, drug and 
cosmetic formulation as adjuvants of antioxidant and antibacterial additives. Other 
uses of chelating agents include water softening, application in the chemical and 
textile industry, in catalysis, in agriculture as fertilizers, in water and soil remediation 






Applications of chelating agents Global consumption 
Pulp and paper manufacturing 32% 
Household and industrial cleaning 24% 
Chemical industry 10% 
Agriculture 8% 
Water and soil treatment 7% 
Food, drug and cosmetic formulations 5% 
Other applications: MEDICINE, textile industry, 
metal manufacturing etc. 
14% 
 
Figure 1.3. Worldwide consumption of chelating agents (weight).11 
 
Chelating agents are also extremely important for life in general, in fact endogenous 
chelating agents are produced by all sorts of living organisms and they are responsible 
for many physiological processes such as enzymatic activity, oxygen transport, metal 
accumulation and detoxification etc.11–15. Deferoxamine B (Figure 1.4), for example, 
is a natural occurring siderophore produced by Streptomyces pilosus, and it exhibits 
strong affinity and selectivity towards Fe3+. For this reason, deferoxamine B is an 
important drug for the treatment of iron intoxications and for illnesses characterized 







Figure 1.4. Deferoxamine B. 
 
Owing to the importance of chelating agents in all the above cited fields, they have 
been an important and active research topic for both academia and industry since the 
beginning of 19th century as documented by the increasing number of dedicated 
scientific articles and patents published yearly.10,12 In fact, some properties of 
chelating agents are still to be improved nowadays, i.e. chelation efficiency, toxic 
reagents (such as formaldehyde and cyanides) and non-renewable starting materials 
(ethylenediamine and diethylenetriamine) (Figure 1.5) and experimental protocols 
(such as high temperature, long reaction times and management of wastes) required 
for their synthesis,18 biodegradability, toxicity (for example NTA is demonstrated to be 
cytotoxic to cell cultures and mammals)19 and many others.  
 
 
Figure 1.5. EDTA and the most of chelating agents can be prepared by two synthetic 
strategies, cyanomethylation (first step) and hydrolysis (top) and alkylation (bottom) 





NTA (nitrilotriacetic acid, Figure 1.7) and EDTA were the first two chelating agents 
discovered (1936), marketed and exploited for almost all the above cited application 
and in the year 2000 the production of chelating agents has exceeded the worldwide 
scale of 200,000 tons/year.13  
From a chemical point of view chelating agents can be divided into different classes 
such as polyaminocarboxylic acids, phosphonates and carboxylates. 
Polyaminocarboxylic acids are the most common chelating agents and they are used 
for all the above cited application and are able to bind strongly almost all metals. This 
class is represented, for example, by EDTA, NTA, DTPA 
(diethylenetriaminepentaacetic acid), IDS (iminodisuccinic acid) and DOTA (1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid). 
Phosphonates are mainly used for industrial cleaning, water softening and in 
household products and they bind strongly to almost all metals. The main 
representatives of this class are DTPMP (diethylenetriaminepentamethylene-
phosphonic acid), EDTMP (ethylenediaminetetramethylenephosphonic acid) and 
NTMP (nitrilotrimethylphosphonic acid). 
Carboxylates are much weaker chelating agents, are particularly selective for calcium 
and zinc and are mainly used as cleaning agents and in food industries for their 
biodegradability. This class is represented, for example, by gluconates, oxalates and 







Figure 1.6. Most common chelating agents. 
 
The efficiency of a chelating agent in the coordination of metal ions, can be 
determined through potentiometric titration, UV and NMR analysis. These tests 
establish the acid-base behaviour of chelating agents and the affinity towards different 
metal ions, leading to the determination of the stability constant of the corresponding 
metal complexes. For this experiment the compounds undergo an initial classical acid-
base titration, which is preliminary and fundamental to establish the formation 
constants of the relative complexes. Since ligands usually possess many amino and 
carboxylic groups, they often present multiple protonation constants. (Equation 1.1) 
 
𝐾𝑖





Equation 1.1. The various protonation constants (K) are indicated with a subscript “i", 





Then the same molecule is titrated in the presence of a fixed concentration of the 
metal ion to be examined, obtaining the corresponding stability data. High 
thermodynamic stability and considerable kinetic inertia is required to avoid 
dissociation of the complex. 
Moreover, in solution there may be anions capable of competing with the chelating 
agent for the formation of stable bonds with the metal ion present in the complex. 
These anions can subtract the metal from the complex and precipitate it in the form of 
salt or hydroxide. For example the Fe3+ ion at pH values greater than 5.5 precipitates 
from the complex with EDTA generating Fe(OH)3. Some species capable of altering 
the balance related to the formation of the complex are, among others, phosphates, 
carbonates, silicates and citrates.  
In fact, the complexation reaction is an equilibrium between the ligand in its completely 
dissociated form, the metal ion and the complex. 
The complexation reaction can be influenced by the pH of the system and by the 
presence of ions that can compete for the bond with the metal. The completely 
dissociated form of the chelating agent yields more stable complexes than protonated 
species and the concentration of the completely dissociated form is higher at high pH 




Figure 1.7. Influence of pH in the complexation reaction.  
 
Biomedical applications of chelating agents 
Among all previously mentioned applications of chelating agents, their use in medicine 





syndromes, in cancer treatment, in diagnostic imaging etc.) is the main topic of this 
thesis.  
In the biomedical field, a chelating agent must have the following characteristics to be 
considered for human application: 
• High thermodynamic stability: the metal complex must be stable, i.e. it should not 
dissociate easily to prevent the metal ion leaching and its spreading unbound in the 
organism causing toxicity. (Equation 1.2) 
 
M + L ⇄ ML          Kf = [ML] / [M] [L]          Kd = [M] [L] / [ML]       
Equation 1.2. Complexation reaction and its thermodynamic constants.  
 
• High kinetic inertness: the complexation reaction must take place quickly, but 
decomplexation reaction must be slow (kinetic inertness) to avoid unwanted release 
of toxic free metal. For example, if the metal is radioactive, excessive decay must be 
avoided during complexation.  
 
• Selectivity: the chelating agent must be selective for the metal of biomedical interest 
and other physiologic metals should not compete for the ligand, causing the leaching 
of the toxic metal. 
 
• Solubility: the chelating agent must be very soluble in the formulation (usually 
hydrophilic) of biomedical use (intravenous administration usually) and, of course, in 
biological fluids (hydrophilic too). 
 
• Toxicity: the metal complex must be stable and must not release the toxic metal in 
the organism. Free metal ions are able to coordinate oxygen, nitrogen and sulphur 
atoms physiologically present in cell membranes and biological macromolecules 
resulting in alterations of the dynamic equilibrium indispensable for life. This can 
result, for example, in enzyme inhibition, protein conformational changes or alteration 
of membrane potentials. Moreover, many metal ions, such as Gd3+, can interfere with 
Ca2+ metabolism occupying its natural binding sites. Free chelating agent can also 





such as Ca2+. Again, the intact complex can induce a wide variety of toxic effects such 
as a change in osmolarity between intracellular and extracellular compartments. This 
cause water to flow from inside to outside cells inducing cellular and circulatory 
damages. Moreover, metal complexes for diagnostic use should not show 
pharmacologic activity, side effects or other activities apart from the diagnostic feature 
(e.g. the contrast effect).21 
 
• Good clearance profile: the metal complex must be quickly and completely 
eliminated from the body. Complexes with low molecular weight are quite safe due to 
their efficient excretion from the body. This minimizes the exposure to the chelate and 
reduces the chance that slow uptake processes could internalize the complex in cells. 
Instead, complexes bound to macromolecules present a slow excretion, which 
increase the odds of cellular uptake, leading to the release of potentially toxic by-
products, including free metal ions. 7,22–25 
 
Chelation therapy 
Chelation therapy exploits chelating agents to form stable complexes with toxic 
metals, making them harmless and easily eliminated from the organism. Moreover, 
recent literature has proposed chelation therapy as an adjuvant treatment also for 
other pathologies such as hypertension, infections, angina pectoris and metabolic 
diseases.26–29 
As an example of a ligand exploited for chelation therapy, we mention TETA 
(triethylenetetramine, Figure 1.8) hydrochloride, which is a copper chelator used in 
the treatment of Wilson's disease, an autosomal recessive inherited genetic disorder 
responsible for the accumulation of copper in tissues. The main symptoms of Wilson's 
disease are hepatolenticular degeneration and neuropsychiatric and liver disorders. 
Another example of drug for chelation therapy is EDTA, which is exploited to cure 
patients with heavy metal intoxication (such as lead poisoning), since it forms easily 







Figure 1.8. TETA, a drug for copper chelation therapy. 
 
Radiography  
Radiography (RX) is the first imaging technique discovered and exploited for medical 
application and it takes advantage of X-rays to acquire images of the body.  
X-rays are electromagnetic radiation with wavelengths between 0.01 and 10 nm and 
are generated by a high-voltage vacuum tube that accelerate electrons from a cathode 
to a tungsten alloy anode. During this process, accelerated electrons release energy 
in the form of X-rays (Bremsstrahlung or deceleration radiation), whose energy 
maximum is dictated by the energy of incident electrons.  
In a RX clinical exam, X-rays pass through the human body and the different tissues 
(e.g. bone and muscle or pathologic and healthy) have different and characteristic 
transparency to X-rays, generating different contrast on an image in grayscale. 
Tissues that strongly absorb X-ray (e.g. bones) appear bright while other that absorb 
poorly (e.g. air) appear dark. (Figure 1.9) 
 
 






However, sometimes, the physiological contrast of human tissues is not sufficient to 
allow physicians to distinguish between two nearby tissues or to highlight a damage. 
X-ray contrast agents (or X-ray-opaque substances) represent the best solution to this 
problem, in fact, when administered they increase the radiologic visibility of some 
organs.  
X-ray contrast agents consist in high density (ρ) materials and/or atoms with high 






Equation 1.3. μ = X-ray absorption coefficient, A = atomic mass and E = X-ray energy.  
 
Therefore, a good X-ray contrast agent, suitable for clinical application, should 
present, in its structure, atoms with high Z to obtain a high X-ray absorption efficacy. 
Barium sulphate is an example of clinically approved X-ray contrast agent, which, 
administered orally or with an enema to a patient, allows to acquire useful images of 
the gastrointestinal tract for anatomical and pathological investigation. In fact, usually, 
soft tissues are poorly radiopaque and therefore not visible in a routine X-ray exam 
without a contrast agent.31 
 
Computed tomography 
Computed tomography (CT) is one of the most widespread clinical diagnostic imaging 
tools largely used in hospitals.  
CT exploits X-rays that, passing through the human body, decrease in intensity 
according to the density of the crossed tissue. The intensity of the original fan beam 
is known, and its decrease is measured by a detector located on the opposite side of 
the X-ray tube and a software converts the attenuation values into an image. 
By slowly rotating and moving the fan beam and the detector around and across the 
whole anatomic region to examine, the CT apparatus acquires cross sections of the 






CT is a very powerful diagnostic technique for the imaging of various tissue and organ 
systems in both physiological and pathological condition. (Figure 1.10)  
 
 
Figure 1.10. A) Schematic representation of a CT apparatus. B) 2D CT scan of a tibial 
fracture (circled in red). C) 3D reconstruction of the same bone fracture as in B (circled 
in red).  
 
However, if the contrast between two anatomical regions is not enough for diagnostic 
purposes, the application of CT contrast agents can enhance the difference between 
two close tissues.  
CT CAs, dealing with X-rays as RX CAs, exploit the same principle explained in the 
previous section, i.e. they present, in their structure, atoms with high atomic number 
(commonly iodine or bromine) and are frequently used in clinical analysis to obtain 
suitable images of soft tissues.2,32,33 
As representative and important examples of CT CAs we can mention iopamidol and 








Figure 1.11. Iopamidol and iomeprol, two CTCAs. 
 
Magnetic resonance imaging 
 
Basics of NMR 
Nuclear magnetic resonance (NMR) is a physical phenomenon which arises from the 
interaction between three main actors, an atomic nucleus, a magnetic field and a radio 
frequency pulse. 
The first actor, the atomic nucleus, can be seen as a rotating sphere, with a certain 
angular momentum (P) which is responsible for the generation a magnetic momentum 
(μ).  
The ratio between the magnetic momentum and the angular momentum is called 
gyromagnetic ratio (γ) and is typical of each atom nucleus. 
(Equation 1.4) 
μ = γ P 
Equation 1.4. μ = magnetic momentum, γ = gyromagnetic ratio, P = angular 
momentum.  
 
Moreover, nuclei with odd mass (A) and odd or even atomic (Z) numbers have a half-
integer magnetic quantum number (I) (such as 1H, 13C, 19F, 31P = 1/2 and 11B = 3/2), 
nuclei with even A and odd Z have an integer I (such as 2H, 14N = 1 and 10B = 3) and 





and 16O). Nuclei with I = 1/2 are magnetic dipoles, while those with I > 1/2 behave as 
quadrupoles owing to the non-spherical distribution of their nuclear charge. For the 
sake of simplicity and since their importance in NMR, from now on, if not otherwise 
specified, it will almost exclusively talk about the former group (i.e. those with I = 1/2). 
These nuclei, being magnetic dipoles, can align themselves to an external static 
magnetic field (B0), the second actor, being parallel or antiparallel to it in an almost 
equal amount. 
NMR in general, requires very strong magnetic fields, usually stronger than 1 T. The 
nuclear spin state parallel to B represents the ground state, with a tiny excess of this 
alignment (in respect of the antiparallel one) and the NMR phenomenon arises from 
this slight excess. Moreover, this little excess grows proportionally to B0 since an 
increase of the latter rises the energy barrier between the two spin states (parallel and 
antiparallel).  
In an NMR experiment we observe signals arising from this tiny difference which is 
called macroscopic magnetization (M0). (Figure 1.12) 
 
 
Figure 1.12. Schematic representation of (from left), a NMR-active nucleus, its 
alignment to a magnetic field, the resulting macroscopic magnetization and the 
increasing of the energy difference between excited and ground state with the 
increasing of B0. 
 
The third actor is the radiofrequency (rf) pulse, whose fluctuating magnetic field (B1) 
is perpendicular to B0, and causes M0 to align perpendicularly to B0 (and parallel to 
B1). The latter phenomenon is called excitation, and after that the radiofrequency is 
turned off and M0 can go back (relax) to its original position (parallel to B0). Now, M0 
is rotating along its axis (angular momentum) and meanwhile it is relaxing (returning 





a flicked rotating spinning top. The frequency of precession (ω0) is typical of a certain 
nucleus, in a given magnetic field, in a certain chemical environment and in NMR 
experiments gives, once measured and elaborated, precious information about 
molecular structure.35 (Equation 1.5) 
 
ω0 = γ B0 
Equation 1.5. ω0 = precession frequency, γ = gyromagnetic ratio, B0 = magnetic field.  
 
Since the energy difference between ground state (M0 parallel to B0) and excited state 
(M0 perpendicular to B0), unlike other spectroscopic techniques, is very small (in fact 
just a rf is enough!) relaxation is not spontaneous and must be encouraged.  
In fact, two main different relaxation phenomena are altogether responsible for M0 to 
return back to its original position, and they are longitudinal relaxation and transversal 
relaxation. 
Longitudinal relaxation time (T1) is an exponential time constant that indicates the 
amount of time needed for M0 to return parallel to B0 along Z axis (i.e. the axis along 
with B0 lays). Longitudinal relaxation accounts for enthalpic interactions between the 
excited nucleus and the environment, for dipolar coupling with other spins or for 
interaction with paramagnetic particles (i.e. with unpaired electrons). Here the energy 
is lost as heat transferred to other nuclei as vibrational and rotational energy. In fact, 
moving particles in the environment (especially paramagnetic ones) creates a 
complex magnetic field and a distribution of frequencies among which an excited 
nucleus can find its proper resonance frequency thus relaxing quickly.  
Transversal relaxation time (T2), instead concerns the disappearance of the signal in 
the xy plane (perpendicular to B0), it is an entropic phenomenon and T2 is always 
shorter than T1 and always an exponential phenomenon. Transversal relaxation is 
caused by spin-spin interactions between the excited nuclei and other spin systems 
which dephase the signal (i.e. the various magnetic moments lose their precessing 







Figure 1.13. Schematic representation of (from left), excitation of M0, its alignment to 
B1 and relaxation with its parameters. 
 
Basics of MRI 
When a person is placed in an NMR apparatus we speak about magnetic resonance 
imaging (MRI) and some important differences from  single molecules  NMR  must be 
explained. 
First of all, in MRI just 1H nuclei are imaged (those of water, triglycerides, membrane 
phospholipoids and many other biological molecules) since their high concentration 
in tissues, since 1H has an isotopic abundance close to 100% and since its high γ and 
μ. However, also 13C, 31P and 19F – based experiments are gaining importance in MRI 
for similar reasons, which will be explained later.  
In MRI a fourth important actor comes on the stage, i.e. gradients. Note that gradients 
are very important also for NMR in general, but for the sake of simplicity here we are 
just dealing with their implications in MRI. A gradient is a known linear variation of the 
magnetic field in respect of the position, superimposed to B0 for few milliseconds. The 
gradient is voluntarily introduced in the “sample” by the operator and it is used to 
localize the signal coming from a particular spot in the body. Of course, different types 
of protons in different tissues (such as tumors and healthy tissues) have different 
relaxation times, different concentration of water (so different intensities of the signal) 
and therefore one can spot a difference between them on an image, but one must 
also now where this particular signal comes from.23 This is the role of gradients, in a 
magnetic field gradient nuclei experiencing a higher magnetic field absorb a higher 





absorption frequency and nucleus position in space. Applying gradients variable from 
place to place by the operator along the three dimensions (x, y, z) one can understand 
from which spot that particular signal comes from or choose a “slice” of the body to 
image. The images picturing the various slices of the body can be used to compute a 
3D representation of the target organ.36 (Figure 1.14) 
 
 
Figure 1.14. A) General scheme of an MRI apparatus. B) and C) MRI images obtained 
after intravenous injection of Gd-AAZTA-MADEC (a blood pool agent) in a mouse 
after, 2 min (B) and 30 min (C). 
 
As stated above, in a normal MRI exam the contrast between different tissues is 
obtained thanks to the different relaxation times of different tissues, therefore an 
image can be T1 or T2 weighted. Another parameter often used in MRI is T2*, which 
considers both T2 and all magnetic field inhomogeneities typical of the sample and is 
usually much smaller than T2.23 Weighting images with these parameters is useful to 
image different tissues, for example T1-weghted images gives high signal for fat, T2-
weghted images present high signals for water-rich spots (such as tumors, edemas, 
inflamed tissues etc.)37 and T2*-weighted images are useful to image iron rich tissues 
such as hemorrhages.38 
Obviously, there are many other weighting techniques (such as proton density) and 
many other methods in a MRI pulse sequence (such as spin echo) we are not deeply 





difference between two close tissues and therefore images must be acquired 
administering to the patient a suitable MRI contrast agent.23  
 
MRI contrast agents 
Every year, in hospitals all around the World tens of millions of contrast-enhanced 
MRI exam are performed. In fact, 50% of the total MRI clinical exams take advantage 
of MRICAs. They usually consist in injections administered to the patient some 
minutes/hours before the exam, however recently, innovative oral MRI CAs have been 
investigated. MRI contrast agents might be classified in many categories based on 
their structure or on their contrast effect.  
Moreover, MRI CAs can also be classified according to their biodistribution in three 
categories, extracellular, intracellular or organ specific MRI CAs. 
The most common MRI CAs belong to the “extracellular” group and are typically 
exploited for the detection of tumor masses, for example in the brain. MRI CAs are 
usually administered parenterally, then they distribute in a non-specific way in the 
plasma and in the interstitial space and finally are eliminated from the organism by 
renal excretion after a period of 17 hours circa.22 
 
T1-contrast agents, paramagnetic ions 
T1-contrast agents, as stated above, are paramagnetic particles that have the ability 
to interact with excited nuclei (here 1H of water in the body) and make them relax 
much quickly enhancing the signal (positive contrast agents). Among paramagnetic 
materials, Gd3+ represents a gold standard in clinic thanks to its seven unpaired f 
electrons, in fact. every year almost fifty tons of gadolinium are administered to 
patients. However, also Mn2+ (five d unpaired electrons), Fe2+ (four d unpaired 
electrons) and Fe3+ (three d unpaired electrons) have been successfully exploited as 
MRI contrast agents (CA). 
Since free metal ions are very toxic for the human organism, paramagnetic ions must 
be imprisoned in chelating agents to serve as MRI CAs.  
All T1-MRICAs share a common structure pictured in Figure 1.15, with a chelating 






Figure 1.15. General structure and features of a MRICA. 
 
The relaxivity of a MRICA is a parameter which depends on the parameters pictured 
in Figure 1.15 and on MRICA concentration in the organism, the higher the relaxivity, 
the better is the MRICA. (Equation 1.6) 
  
1/T1 = 1/T1 0 + r1[CA] 
Equation 1.6. T1 = relaxation time in the presence of a CA, T1 0 = relaxation time of 
pure water, r1 relaxivity of the CA, [CA] = concentration of the CA.  
 
In fact, the paramagnetic ion must significantly increase the rate of relaxation of water 
protons in a target organ or in the whole body, generating a contrast effect in a non-
toxic dose. Moreover, the CA must be stable in the body (i.e. must not release the 
metal) and must be completely eliminated immediately after the exam, without 
pharmacologic effects. 
Water molecules directly bound to the metal, the coordinated water molecules (inner 
sphere), relax really fast, however also other water molecules really close to the ligand 
(and maybe bound to it for example by means of an hydrogen bond) relax faster than 
in the absence of a CA (second hydration sphere). In fact, q (numbers of water 





the more water molecules the metal binds (directly or indirectly), the higher the 
relaxivity is. But one must pay attention, since a metal generally has a “fixed” 
coordination number (C.N.), the more water molecules it coordinates, the less room 
is left for the chelating agent, the more unstable the complex is, the more toxic free 
metal is released in the organism. For example, Gd3+ has a C.N. = 9, and in a typical 
gadolinium based MRICA q = 1 – 2 to obtain the right balance between acceptable 
stability and efficient relaxivity. Therefore, the typical chelating agent for gadolinium-
based MRICAs has a denticity (κ) = 7 – 8. However, q can be increased also acting 
on the second hydration sphere, introducing in the ligand non coordinating 
electronegative functional groups prone to form hydrogen bonds with water (i.e. 
hydroxyl groups, phosphate, phosphonates etc.). 
Instead, τm is the residence time of inner sphere water and it is = 1/Keq, i.e. the 
exchange constant of coordinated water. The higher τm is, the better is the relaxivity, 
since a water molecule binds to the metal, quickly relaxes and it is immediately 
replaced by another water molecule ready to relax.  
The proton-metal distance in the inner sphere (r) and in the outer sphere have a great 
impact on relaxation, in fact relaxivity is inversely proportional to proton-metal distance 
with a factor of 106. Therefore, in an ideal MRICA a and r should be minimized. 
Rotational correlation time (τR) indicates the rotational mobility of the paramagnetic 
complex and grows as a function of molecular weight of the latter. Relaxivity and 
complex stability increase as the rotational correlation time is increased. In particular, 
the paramagnetic complex catalyses the relaxation of water nuclei when the rotational 
speed of the CA matches the precession frequency of the nucleus (resonance 
condition). Since proton, for example, has a precession frequency of few hundreds 
Hz (i.e. 300 Hz at 7 T) and small molecules in water at room temperature rotate much 
faster, their rotation must be slowed down. 
T1e is the electronic relaxation time, it depends on the structure of the chelating agent 
and on the magnetic properties of the metal and increasing this parameter relaxivity 
grows. 
ΤD is the diffusion correlation time, i.e. the rate of diffusion of solvent molecules in 
which the CA is dissolved. As stated above the paramagnetic ion must move to 





paramagnetic center, relax and leave the room for another solvent molecule as quick 
as possible, therefore, high τR values increase relaxivity.23   
Other important parameters for T1-MRICAs are thermodynamic and kinetic stability of 
metal complexes. As stated above, free metal ions (especially gadolinium) are really 
toxic for the organism, it accumulates for example in the brain, kidney, bone etc. after 
repeated administrations and causes severe side effect especially in compromised 
patients (e.g. with renal failure).24,25 To avoid these problems, the metal complex must 
show high thermodynamic and kinetic stability, being stable over time also in  the 
presence of physiologic competing metal ions (i.e. Ca2+, Mg2+ etc.), chelating 
molecules (i.e. aminoacids, phosphates etc.) or acidic pH. 
The following table reports the values of the parameters reported above for some 
MRI-relevant Gd3+ complexes (Table 1.2), whose structure and properties will be 
discussed in the following pages. 
 
Ligand κ LogKGdL LD50 kobs τm τR q r r1 r2 
EDTA 6 17.7 0.3 140000 - - 3 - - - 
DTPA 8 22.46 5.6 1.2 130 58 1 3.13 3.8 4.4 
DOTA 8 25.3 11 0.021 108 77 1 3.13 4.2 4.75 
AAZTA 7 20.24 - - - 74 2 - 7.1  
HP-DO3A 8 23.8 12 0.064 - - 1 - 4.4 5.5 
DO3A 7 21.1 7 - 9 2.37 77 66 2 3.15 4.8 - 
BOPTA 8 22.59 - - - 88 1 2.96 6.7 8.9 
NOTA 6 13.7 - - - - 3 - - - 
PCTA 7 - - - 34 70 2 3.1 6.9 - 
DOTP 8 28.8 - - - 73 3 - 3.5 - 
 
Table 1.2. Complexometric and relaxometric properties of some MRI-relevant Gd3+-
complexes. LogKGdL = complex stability constant; LD50 in mouse, intravenous, 
[mmol/kg]; kobs = acid dissociation rate [103 s-1]; τm = [ns]; τR = [ps]; r = distance metal-






Drug regulatory agencies around the world (i.e. E.M.A., F.D.A. etc.) have approved 
for human use (since 1989) ten MRICAs, and some of them are still commercially 
available. (Figure 1.14) 
 
 
Figure 1.14. Clinically approved MRICAs. 
 
These MRI CAs might be all exploited for general purposes which require the 
distribution of the CA in all the organs (i.e. detection of tumours, brain lesions etc.), 
however some of them present peculiar characteristics. For example, Gd-BOPTA and 
Gd-EOB-DTPA, thanks to their benzylic lipophilic chain, are accumulated 
preferentially in the liver and their contrast effect is optimal in this anatomical 
region.22,41–44 On the other hand, gadofosveset works as a blood pool agent, thanks 
to its lipophilic chain particularly selective for binding human albumin (HSA). In fact, 
being the CA conjugated to HSA (a large protein), it cannot exit from blood vessels 
and for this reason it is specific for blood imaging (angiography). This might be 
particularly useful since angiography, usually, is performed exploiting x-rays, 
radioactive tracers and invasive injection techniques. Moreover, the supramolecular 
adduct between a T1-MRICA and a macromolecule (i.e. HSA) shows an increased 
relaxivity since bigger is the molecule, slower it moves and therefore higher is τR.22,45,46  
Mn-DPDP is an example of Mn-based MRICA, which are interesting CAs with some 
differences compared to Gd-based MRICAs. First of all, Mn2+ has just five unpaired d 
electrons while Gd3+ has seven f unpaired electrons, making the latter a more suitable 





ideal ligand should have a κ not higher than six, being hexadentate ligands particularly 
interesting, since they have a coordination site for one water molecule on the metal. 
(Figure 1.15)  
Mn2+ ions also tend to form stable complexes with ligands with κ = 4 and q = 2, such 
as porphyrins (i.e. TPPS).22   
 
 
Figure 1.15. Selected chelating agents forming stable complexes with Mn2+ with the 
stability constant for the Mn-complex in brackets. As one can see, Mn-complexes are 
rather more unstable than Gd-complexes.  
 
Moreover, manganese has the great advantage of being much less toxic than 
gadolinium (being an essential element in human metabolism). However, due to since 
the general instability of Mn-complexes and their limited efficacy as MRICAs, at the 
moment the market and the scene are dominated by Gd-based MRICAs.22,47 
It is important to point out, looking at Figures 1.14 and 1.15, that MRI-relevant 
chelating agents can be divided in linear (i.e. BOPTA, DTPA, DPDP etc.) and 
macrocyclic (e.g. DOTA, HP-DO3A, DO3A etc.), depending of their chelating 





complexes too weak (and for instance too toxic) for human application. Macrocyclic 
ligands (i.e. those bearing a 12-membered or a greater cycle in their structure) are 
nowadays the best choice for the preparation of MRI CAs, since they represent the 
best compromise between contrast effect and complex stability.  
For example, P03277 (Figure 1.16) is a macrobicyclic heptadentate MRICAs 
approved for clinical trials in 2015 (which are still ongoing). Its Gd-complex is very 
stable thanks to the macrocyclic structure and it shows high relaxivity thanks to its q 
= 2 and the presence of hydroxyl groups which increase the effect on relaxation of the 
second hydration sphere.48 
However, macrocyclic ligands and complexes thereof are usually plagued by difficult 
and expensive syntheses and purifications, therefore their preparation suffers of 
drawbacks such as low yields and high costs.49–51 
Mesocyclic ligand (e.g. AAZTA), otherwise, present a clever solution to these 
problems, forming stable chelates with MRI-relevant metals and being easily prepared 
by inexpensive and simple procedures. Mesocyclic ligands consist in chelating agents 
bearing one or more ring with less than 11 members. AAZTA (Figure 1.15), the first 
example of this class, is a heptadentate ligand (therefore with q = 2) and shows an 
optimal relaxivity (7.1 mM-1 s-1 at 20 MHz and 298 K) for application in MRI.52 
As stated above, also Fe2+ and Fe3+, chelated by a proper ligand, might be useful as 
MRICAs. Fe2+-DTTACN (Figure 1.16) offers an example of this technique, consisting 
in a mesocyclic chelating agent based on TACN (1,4,7-triazacyclononane) and have 







Figure 1.16. P03277 and Fe-DTTCT, two recently developed MRICAs. 
 
However, being mesocyclic and macrocyclic ligands the main theme of this PhD 
thesis, they will be treated in more detail in the following pages.  
 
T2-contrast agents 
As stated above, T2-MRICAs are substances able to show a contrast effect in T2-
weighted images acting as negative CAs (i.e. reducing the signal coming from the 
“highlighted” zone). The effect on the relaxation of water protons, obtained with T2-
MRICAs, can be measured in a very similar way to T1-MRICAs, i.e. following Equation 
1.7. 
 
1/T2 = 1/T2 0 + r2[CA] 
Equation 1.7. T2 = relaxation time in the presence of a CA, T2 0 = relaxation time of 
pure water, r2 relaxivity of the CA, [CA] = concentration of the CA.  
 
Also in this case, higher is the relaxivity of the T2-MRICAs and more efficient is as a 
CA. As seen in the previous section, paramagnetic ions might work as T2-CAs but 
with limited efficacy, but also the contrary is true. However, some compounds show a 





materials in which the solid part is constituted by nanoparticles (1 μm – 50 nm) with a 
superparamagnetic iron oxide core (the active part of the CA) and a biocompatible 
coating which reduces the overall toxicity of the CA (such as dextran, citrate, oleate 
etc.). The coating has also the role of avoiding particles aggregation and reducing 
immunogenicity of the T2-MRICA.  
Moreover, since they exhibit a strong magnetic effect, they generate great magnetic 
inhomogeneities and for this reason they can be exploited also as CAs in T2*-weighted 
images.  
An example of T2-MRICA is ferumoxytol, which have been approved in 2009 for 
clinical trials as blood pool contrast agent. Ferumoxytol consist in a colloidal solution 
(isotonic and pH neutral) of nanoparticles with a carbohydrate coated 
superparamagnetic iron oxide, which is administered as an injection. This CA, being 
gadolinium-free, might represent an alternative to Gd-based MRICAs in patients with 
chronic kidney disease, working both as T1 and T2 -MRI CA.  
However, since this results are very promising, concerning about their 
pharmacokinetic (i.e. elimination of the drug from the body) and their safety are still 




The CAs so far analysed, act on water protons (physiological) since the MRI 
apparatus records images on the “channel” of 1H. But as stated above, also other 
nuclei are suitable to record MRI images and in this section the 19F-based MRI CAs 
are analysed. Of course, the body only contains trace amounts of fluorine, therefore 
the background noise is almost zero and the contrast effect is maximised. 
Nonetheless, a CA is always needed to obtain an image and there are many different 
solutions. In fact, in principle any non-toxic fluorinated (19F, which has a natural 
abundance of 100%) compound can be used as 19F-MRICAs, and here some 
examples are reported without claiming to be complete. (Figure 1.17)22,55,56 
An interesting improvement of 19F-MRICAs is obtained with fluorinated paramagnetic 





of the paramagnetic centre to fluorine atoms significantly shortens longitudinal and 
transversal relaxation rates of fluorine atoms with a mechanism similar to the one 
explained above for water. (Figure 1.17)22,57 
 
 
Figure 1.17. Examples of 19F-MRICAs. 
 
Chemical Exchange Saturation Transfer MRICAs 
The CEST (Chemical Exchange Saturation Transfer) phenomenon is acquiring a 
continuous and increasing interest in the field of MRI. It exploits the exchangeable 
protons of a suitable CA to decrease the intensity of the signal of bulk-water, 
generating a negative contrast effect. During a CEST experiment, a radiofrequency 
pulse, at the frequency of the exchangeable proton, saturates the latter and 
meanwhile the acquisition is running on the usual frequency of water. Since the 
saturated proton exchanges with the water protons, the saturation is transmitted too 
and spreads all over the bulk, reducing the intensity of the water NMR signal. The 
fastest the exchange and the farther are the exchangeable proton and the water 







Figure 1.18. Schematic representation of CEST principles. δ1 and δ2 are respectively 
the chemical shift of the exchangeable proton of the CA and of water.  
 
All compounds with exchangeable protons are potential CEST MRI CAs, in particular 
those bearing an amide, a hydroxy, an amino group or similar. Therefore, metabolites 
physiologically present in cells (i.e. proteins, amino acids, lactic acid) could do the 
trick as well, but unfortunately, they are naturally too diluted and CEST MRI CAs are 
usually effective only in high concentration.58 However, glucose for example, 
administered intravenously, has been successfully exploited as a CEST MRI CA 
thanks to its exchangeable OH protons. Cancer cells tend to accumulate nutrients, 
and glucose as well, faster than healthy ones and therefore its use as CEST MRI CA 
has led to a significant contrast effect in the imaging of tumours (such as glioblastoma) 
in both mice and human. Obviously, glucose has been already approved for 
intravenous administration in human and it is perfectly biocompatible, biodegradable 
and tolerated.59,60 (Figure 1.19) 
“Drug repositioning” is an important issue in CEST MRI, since it is a novel and very 
versatile technique requiring only an exchangeable proton and a well-established 
safety profile in human even in high doses. For example, iopamidol, a CT CA 
approved for human use, meets all these requirements and presents also two different 
amide protons thanks to which it is sensible to tiny pH variation of tissues. A different 
pH value can in fact dramatically affect (reduce or increase) the proton exchange rate 
and the CEST effect. Pathologic tissues, such as tumours or ischemic lesions, are 





and for this reason, iopamidol has been used as a contrast agent in murine tumor 
model (i.e. breast cancer) with promising results.61,62 (Figure 1.9) 
Complexes of paramagnetic ions offer a great improvement in the CEST technique 
(paraCEST), in fact the water protons directly bound to the metal centre or 
exchangeable protons in the second sphere, possess a greater distance, in terms of 
chemical shift, from the bulk water signal then any diaCEST CA. DOTAM complexes 
of lanthanides (Nd3+, Eu3+, Tb3+, Tm3+, Dy3+ and Yb3+) and of transition metals (Fe2+, 
Co2+, Cu2+, and Ni2+) show a strong CEST effect and have been also exploited as a 
pH sensible probes.63 (Figure 1.19) 
Finally, CEST CAs, suitably functionalised with redox responsive moieties, may serve 
as oxygen or NADH concentration sensors. For example, the Eu3+ complex of DO2A-
(gly)2 with two N-methylquinolinium residues, as redox responsive moieties, have 
shown interesting CEST properties, increasing the contrast effect as the NADH 
concentration increase as consequence of a variation in the coordination sphere of 
the paramagnetic ion.22,64 (Figure 1.19) 
 
 
Figure 1.19. Selected examples of CEST MRICAs.  
 
Hyperpolarised MRICAs 
As explained above, MRI suffer from the limitation that the signal (deriving from 
relaxing nuclei) arises from a small excess of nuclei aligned parallel (ground state) to 





compound with a great excess of spins in the ground state or in the excited state, the 
signal, deriving from the relaxation of all of them, would be significantly higher. This 
phenomenon, called hyperpolarization, can be obtained in four different ways, i.e. 
optical pumping, dynamic nuclear polarization, parahydrogen-induced polarization 
and signal amplification by reversible exchange.  
In optical pumping light is used to raise nuclear spins from a lower energy level to a 
higher one, obtaining in this way the population (of spin) inversion (making them 
equally aligned) typical of hyperpolarised systems.22,65 (Figure 1.20) 
 
 
Figure 1.20. Example of optical pumping. 
 
In dynamic nuclear polarization, hyperpolarization is obtained by means of a stable 
radical (e.g. trityl) cooled to 1 – 5 K in a strong magnetic field (3 – 5 T). In these 
conditions radical electron spins are all aligned to the external magnetic field and this 
hyperpolarisation can be transferred to a 13C atom using a microwave radiation close 
to the magnetic resonance frequency of the radical electron spin.66–68 (Figure 1.21) 
 
 





Parahydrogen-induced polarization, instead, exploits parahydrogen (H2 molecules 
with the two atoms nuclear spin aligned antiparallel to each other, therefore 
hyperpolarised) to hydrogenate an unsaturated substrate. These hydrogenation 
reactions must be really fast and normally exploit homogenous catalysis and usually 
rhodium or iridium-based complexes as catalysts. Then, the magnetisation (i.e. the 
hyperpolarization coming from parahydrogen) is transferred to a nearby 13C atom 
through J-coupling, being JH-H and JH-C values close. The selective magnetisation 
transfer from 1H to 13C can be obtained by eliminating quickly all external magnetic 
fields acting on the 13C-marked parahydrogenated substrate and then restoring slowly 
all external magnetic fields (diabatic-adiabatic magnetic field cycling). This 
magnetization transfer can be obtained also with specific radiofrequency pulses or by 




Figure 1.22. Example of parahydrogen-induced polarization. 
 
Signal amplification by reversible exchange involve the coordination of a substrate 
(usually a pyridine) to an organometallic catalyst. Also here, parahydrogen 
coordinates the catalyst as well, transferring its hyperpolarization to the substrate in a 







Figure 1.23. Example of signal amplification by reversible exchange 
 
After hyperpolarization, the contrast agent might be purified, dissolved in an 
appropriate solvent, brought nearby physiological temperature and injected to the 
patient very quickly, to limit the relaxation of the hyperpolarized molecule. Images can 
be recorded with normal a MRI apparatus tuned on the resonance frequency of the 
hyperpolarised nucleus (i.e. in examples above, 13C and 129Xe).  
Dynamic nuclear polarization has been used to prepare hyperpolarised pyruvate 13C-
labeled in position 1. Since tumours present continuous growth and constant nutrients 
supply, hyperpolarised pyruvate (and eventually its metabolites still hyperpolarised) 
accumulates preferentially in the tumour increasing the contrast in this region. Being 
pyruvate an important and central physiologic metabolite, it is safe to use in human. 
(Figure 1.21) 
In principle, every NMR-active nucleus with a long T1 (to ease workup of the contrast 
agent) can be exploited as hyperpolarised MRI CA, and this is the case of 13C and 
129Xe. 
In fact, 129Xe, hyperpolarised by optical pumping, is clinically approved as MRI CA for 








Ultrasound Sonography (US) is a very common and non-invasive imaging technique 
that provides real-time anatomical images in cross sections of soft tissues. US exploits 
ultrasounds, i.e. soundwaves with frequencies higher than 20 kHz, but clinical 
diagnostic US scanners use frequencies between 1 MHz and 20 MHz.  
During an US exam, ultrasound pulses are sent through the patient’s body which 
partially absorbs and partially reflect ultrasound waves (different tissues absorb and 
reflect differently) creating echo effects. The latter, once analysed and processed, 
allows to reconstruct a 2D grayscale image with intensity as a function of echo return. 
(Figure 1.24) 
Resolution of US images improves increasing the ultrasound frequency, while depth 
penetration decreases, therefore the choice of the right frequency allows the operator 
to find a good balance between resolution and depth penetration. This phenomenon 
is caused by the fact that soundwaves with a short wavelength interact better with the 
living matter and therefore they are less reflected. 
US presents several advantages among other imaging techniques, such as low cost, 
safety (no ionising radiation are required), and ease of use and implementation.74,75 
In some US exams, US CAs are exploited to improve US imaging. US CAs are 
prepared with materials characterized by different acoustic properties if compared to 
human tissues. The most common US CAs are intravenously injections of small air or 
gas bubbles (microbubbles) that improve the doppler signal from blood vessels and 
the sensitivity of US technique in general. These microbubbles are typically coated 
with lipids or biopolymers to enhance reflection and signal-to-noise ratio of blood.76 
The external coating might present vector molecule (such as proteins) which can 
target the US CA to a specific cellular type or tissue (such as inflamed tissues).77,78 
US CAs are successfully clinically applied, for example, to study angiogenesis and to 
image microcirculation.76 As an innovative example of general non-targeted US CA 
we mention sulphur hexafluoride microbubbles, with a phospholipidic coating, which 







Figure 1.24. A) Schematic illustration of an US apparatus. B) 2D US image of a 




Optical Imaging comprehends numerous non-invasive imaging modalities applied in 
the diagnostic and biomedical field to detect pathological changes, employing different 
wavelengths of light (UV, visible and near-IR), absorbed, emitted or scattered by 
molecules, cells and tissues.81 (Figure 1.25) 
 
 
Figure 1.25. A) Scheme of an OI apparatus. B) OI image based on haemoglobin 
concentration of breast cancer (the mass is circled in black).82,83 
 
Optical imaging is really an innovative technique that exploits light to excite a contrast 
agent, administered to the patient, and then the CA releases back the photons 
absorbed (usually with less energy, i.e. fluorescence) which are captured by the 





OI CAs can be endogenous (i.e. oxygenated or deoxygenated haemoglobin and 
cytochromes) or exogenous molecules (i.e. fluorescent dyes and lanthanide 
complexes).2 
Chelating agents for lanthanides (i.e. DOTA-like, DO3A-like, AAZTA-like derivatives) 
bearing one or more side arms on their backbone with a fluorochrome can be applied 
as OI CAs or as OI/MRI CAs if the lanthanide is gadolinium.84 Lanthanides-based OI 
CAs offers long luminescent lifetime thanks to the antenna (i.e. the above cited 
fluorochrome) that capture the light energy, promotes its electrons to the triplet excited 
state, which transfers its energy to the metal centre. Moreover, lanthanides 
(particularly Eu and Tb) present suitable and large fluorescence emission in the visible 
region generated from electronic transition in the non-bonding 4f electron shell. Here, 
chelating agent must present a C.N. > 8 to avoid the leaching of toxic metal and the 
coordination of water molecules that could quench the fluorescence. (Figure 1.26) 
 
 
Figure 1.26. Lanthanide-based OICA.85 
 
OI can be combined also with all the other imaging technique to obtain more detailed 
images of a target organ.2 
Moreover, many fluorescent dyes are reported in the literature and some of them are 
currently applied in fluorescent imaging applications, such as indocyanine green (ICG) 









Figure 1.27. Indocyanine green. 
 
OI can image the body at different levels, being useful to acquire images of organs 
and tissues, but also to track cellular and molecular changes in the body. The main 
disadvantage of OI is the scarce depth penetration of light, ranging from < 1 mm for 
UV to few inches for IR.87 
 
Positron emission tomography 
 
Positron emission tomography (PET) is an innovative technique, which exploits 
positron-emitting radionuclides with short half-life to obtain images. In fact, PET CAs 
are necessary to obtain PET scans since, luckily, our organism does not emit 
positrons spontaneously. PET radiolabeled contrast agents are administered 
intravenously at low concentrations and emit positrons that annihilate with neighboring 
electrons generating two opposite collinear γ-rays. Positron-emitting nuclei present an 
excess of protons, which makes them unstable. That instability is rectified by 








Figure 1.28. Schematic representation of a PET apparatus (top) and PET scans 
(bottom) acquired on a mouse xenografted with a A431-CCK2 positive tumour after 
administration of a PET CA at different times. Here the CA consist in the gallium 
complex of an AAZTA-like BFCA (bifunctional chelating agent) linked to a vector 
molecule, i.e. a minigastrin analogue (vide infra).88 
 
Several detectors, placed around the patient, collect the pair of rays emitted by the 
radionuclide and reconstruct the emission point projecting a 2D or 3D image of 
patient’s body.1,2  
PET imaging finds many diagnostic applications including the detection of tumors and 








The first PET-relevant radio nuclides exploited in research and clinic were "non-metal" 
isotopes such as 11C, 13N, 15O, 18F, generated by a cyclotron, i.e. a particle accelerator 
that speeds up protons thanks to a magnetic field.90’91 
These radioisotopes are usually introduced in natural-like molecules and these probes 
and/or their decaying products are naturally occurring biomolecules, therefore PET 
CAs do not alter the physico-chemical and biochemical properties of tissues (except 
for ionizing radiations, obviously).92 
PET CAs work as functional tracers, allowing in vivo diagnostic studies or the 
localization of pathological tissues following their accumulation. in fact, metabolized 
radiopharmaceuticals are accumulated in the “hotspot” (e.g. a tumor) and emit 
positrons or γ rays which are registered by tomographs. 
These radionuclides present covalent bonds to the rest of the contrast agent, 
therefore, for their synthesis, they require common reactions and purification 
procedures. The latter must be quick enough to avoid excessive nuclear decaying 
(which leads to inefficacy) and accurate enough to fulfill (as any other drugs) the strict 
rules of good manufacturing practices.  
Actually, 18F is the clinical gold standard since its availability, ease of introduction in 
organic molecules and its half-life of 110 min, a good compromise between a proper 
(not excessive) radiation exposure for the patient, and a sufficient amount of time for 
operators to react and workup the contrast agent. One of the most widely used PET 
contrast agent is [18F]-fluorodeoxyglucose, also known as 18F-FDG. (Figure 1.29) It is 
used to monitor glucose metabolism and is very important for the clinical diagnosis of 







Figure 1.29. Structure of 2-[18F]-fluoro-deoxy-D-glucose. 
 
Also 11C (another positron emitter isotope) has found valuable diagnostic applications 




Recently, metal radioisotopes have found many applications in PET imaging, 
considering that 11C and 18F-labelled contrast agents display, after all, a very short 
half-life and difficult preparation and purification procedures.  
In fact, 61Cu, 62Cu, 64Cu, 64Ga, 67Ga, 68Ga, 44Sc, 86Y, 89Zr and many other isotopes of 
metal ions are used to prepare PET CAs to study biochemical processes. They 
possess a longer half-life and they may also be easily bound to a vector molecule 
through complexation (vide infra).2,94,95 
Two gallium isotopes are currently available for clinical applications, 67Ga (t1/2 = 78.3 
h by electron capture) has a sporadic role in scintigraphy while 68Ga (t1/2 = 67.7 min, 
β+ emission) has found, in last decade, vast clinical applications. This is mainly due to 
the broad diffusion of benchtop 68Ge/68Ga generators providing 68Ga3+ in acidic 
aqueous solution96 and to the high clinical value of 68Ga-based (PET) 
radiopharmaceuticals97. Moreover, 68Ga has a high positron yield (89%, 1.9 MeV)98 
and its half-life matches the pharmacokinetics of low molecular weight 
radiopharmaceuticals. 
68Ge/68Ga generator, necessary for the synthesis of these innovative PET CAs 






Figure 1.30. Reaction happening in benchtop 68Ge/68Ga generators. 
 
Unlike “non-metal” PET CAs, the introduction of a radioactive metal ion (such as 
68Ga3+) in a diagnostic carrier (say a chelating agent) consists in a simple one-step 
reaction (a complexation reaction).99,100 The ideal chelator must show a high 
selectivity and affinity for the metal ion, a rapid complexation kinetics to avoid an 
excessive decay of the radionuclide and high kinetic inertness to avoid dissociation of 
the complex in the organism before excretion.  
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) is, to date, the gold 
standard for the preparation of metal PET CAs, many DOTA-like chelating agents are 
commercially available, but usually their Ga3+-complexes are formed slowly.101 Many 
other chelating agents have been exploited to prepare PET CAs, such as NOTA, 
HBED and AAZTA98,102–105 (Figure 1.31) 
In particular, AAZTA52 and its derivatives (such as DATA and DATA-like chelating 
agents) (Figure 1.31) possess promising properties for the preparation of innovative 
PET CAs. In fact, they quickly (in less than 15 minutes) and quantitatively form, at 
room temperature, thermodynamically stable complexes with gallium106 scandium and 
other PET-relevant metals.107 
 
 






Single-photon emission computed tomography 
 
SPECT imaging exploits, as CAs, radioactive isotopes properly trapped in a chelating 
agent to limit their toxicity. After administration to the patient, the radiopharmaceutical 
(and metabolites thereof) is accumulated in the points of interest, emits γ rays which 
are registered by γ cameras, rendering an image to the operator. (Figure 1.32) 
 
 
Figure 1.32. A) Schematic representation of a SPECT apparatus. B) SPECT image 
of the brain of a control patient after administration of a SPECT CA (ioflupane, vide 
infra) selective for the dopamine system. C) SPECT image of the brain of a patient 
affected by Parkinson’s disease treated with the same CA as in B.108 
 
To obtain good quality images, the energy emitted by the radionuclides must be 
between 100 and 250 keV. During a SPECT clinical exam multiple 2D projections 
from multiple angles are acquired and sent to a computer dedicated to the 
reconstruction of images. If a 360° rotation is performed, it is possible to obtain an 
optimal 3D reconstruction. However, SPECT imaging has a lower sensitivity and 
resolution than PET.   
Obviously, SPECT imaging mandatory requires a CA to acquire images and, as stated 
for PET CAs, also SPECT CAs can be divided into two categories, “Non-metal” and 
“Metal” SPECT CAs.  
As an example of non-metal based SPECT CAs, we mention ioflupane (123I), a 
clinically approved cocaine/dopamine analogue, which targets the dopaminergic 





the radionuclide is 123I, which decays by electron capture emitting a γ ray. (Figure 
1.33) 
 
Figure 1.33. Ioflupane (123I) is a clinically approved cocaine/dopamine analogue and 
a SPECT CA selective for the dopaminergic system used for Parkinson’s disease 
diagnosis.108 
 
“Metal” SPECT CAs, instead, represent an innovative class of CAs and present the 
same advantages explained for analogues PET CAs, i.e. easy one-pot synthesis, 
tunability and many others. 
Many metal isotopes emit useful γ rays that can be used in clinical SPECT imaging, 
such as 99mTc, 67Cu, 67Ga, 90Y, 111In and 201Tl, and in particular their corresponding 
ions, carefully complexed by chelating agents, can form many different γ emission 
complexes useful as SPECT CAs.109 
The most important element used for SPECT imaging is 99mTc which emits γ rays 
(decaying to 99Tc) with the energy of 140 keV, optimal for the detection with γ 
cameras. Although 99mTc short half-life (about 6 hours) might represent a limitation for 
its clinical application (in fact long complexation procedure could dramatically affect 
the efficacy of the radiotracer), the existence of a dedicated generator makes it easily 
available for diagnostic purposes. 99mTc-based radiopharmaceuticals are exploited to 
image many major diseases, i.e. to detect bone metastases or hidden fractures, using 
as CA a 99mTc-diphosphonate (such as technetium (99mTc) medronate) which is 
accumulated in the bones. 
Other important clinically approved 99mTc-based radiopharmaceuticals are technetium 





blood flow for example in patients with stroke) and technetium (99mTc) sestamibi 
(exploited for the imaging of myocardial perfusion and cancer).110 (Figure 1.34) 
 
 
Figure 1.34. Technetium-based clinically approved radiopharmaceuticals. 
 
Another SPECT-relevant metal-based radionuclide is 67Cu. The divalent ion Cu2+ 
shows a rich coordination chemistry exploited in a wide variety of complexes with 
nitrogen-based ligands, including cyclen (1,4,7,10-tetraazacyclododecane) 
derivatives. This ion has coordination numbers ranging from 4 to 6 and therefore Cu2+-
complexes can assume different geometries ranging from square, square pyramidal, 
trigonal bipyramidal to octahedral shapes. Several 67Cu2+-complexes have been 
designed and synthesized to detect tumors with SPECT imaging.111  
Also 67Ga3+ can be exploited for the preparation of chelates used as SPECT CAs, 





complexes with hexadentate ligands that can satisfy the requirements of this hard 
trivalent ion.112 
AAZTA, DOTA and DO3A derivatives are currently finding vast applications as 
SPECT CAs thanks to their ability to form stable complexes with most SPECT relevant 
metal ions in a reasonable amount of time, compatible with the usually short half-lives 




Targeted CAs are gaining great research and clinical importance in the last few years 
since their impressing diagnostic and therapeutic value. They present many 
differences if compared to classical, general, and simple CAs, such as their complex 
structure and their really high selectivity. In fact, classical CAs are very useful for 
general purpose, for example body scans, molecular imaging of a vast organ such as 
the brain and so on. If the structure of the CA is analogous to a physiological 
substance, classic CAs can become selective for a particular anatomic region (i.e. the 
bone). But targeted-CAs bring selectivity to the next level, through a very general 
technique called bioconjugation, they ensure a high contrast effect in patients with a 
particular (usually pathological) molecular pattern. The latter usually correlate with an 
important pathology (such as cancer) which is highlighted with a selectivity and a 
contrast effect infinitely higher than classical CAs. 
A general structure of a targeted CA is represented in Figure 1.35, a metal (e.g. 
radionuclide, paramagnetic etc.) is chelated by a bifunctional chelating agent (BFCA, 
a chelating agent with a reactive functional group) bound, by means of a reactive 
linker to a vector. When administered to a patient, the targeted-CA searches for its 
target in the body, strongly binds it and, by means of classical imaging apparatus, it 








Figure 1.35. Scheme of a targeted CA bound to its specific physiopathological target. 
 
In the literature there are plenty of examples of targeted-CAs, and some of them have 
become clinically approved in the last few years.1,51,113 
Since a comprehensive review of the subject could not be done here, the discussion 
will be limited to the most relevant examples of targeted-CAs. It will show how their 
structures match with Figure 1.35, hoping that it could serve as a general example 
able to represent also other targeted-CAs reported in the literature. 
The attention will be focused on two recently approved targeted-CAs, i.e. DOTATATE 
(approved by FDA in 2018) and DOTATOC (approved by FDA in 2019).  
They are administered to the patient as complexes of radionuclei including 68Ga, 177Lu, 
64Cu and 90Y and are approved in the diagnosis and therapy of various malignancies 
such as neuroblastoma and brain, gastrointestinal, breast, lung, and lymphatics 
cancer. In fact, as thoroughly explained previously, DOTATATE and DOTATOC 
complexes with the above mentioned radionuclei can be exploited as targeted-PET 
CAs but also as drugs for targeted-radiotherapy. The latter is a great and recent 
breakthrough in cancer treatment: drugs for targeted-radiotherapy consist in 
radiometal chelates bound to a vector selective for a cancer-associated molecular 
signal (i.e. overexpressed hormones receptors). In a similar way to targeted-CAs, 
when administered to the patient, drugs for targeted-radiotherapy seek for their 





there, where needed, a high dose of radiation provided by radionuclei.114 DOTATATE 
and DOTATOC share a common structure, they consist in a radiometal ion (among 
those mentioned above) chelated by a DOTA-like BFCA. DOTA forms stable chelates 
with most transition metals, ensuring that the metal, by means of the chelating agents, 
stays strongly bound to the vector, securing the targeted delivery of the radiotherapy 
dose. This DOTA-like BFCA chelates the metal with the four “cyclen” amine groups, 
with three acetic acid residues and with the carbonyl group of the amide. The vector 
molecule instead consists in a somatostatin analogue (octreotate for DOTATATE and 
octreotide for DOTATOC) selective for somatostatin receptors overexpressed by the 
malignancies listed above. The linker between the BFCA and the vector molecule is 
represented by an amide group. The latter is obtained by the condensation reaction 
between an unprotected carboxylic acid (the reactive group) on the BFCA and an 
unprotected amine group on the vector which is obtained by classical supported Fmoc 
peptides synthesis. The condensation reaction between the vector and the BFCA is 




Figure 1.36. DOTATATE and DOTATOC, recently approved targeted PETCAs and 





However, the synthesis of BFCA and their conjugation to vectors of biomedical 
interest is treated in more detail in Chapter 4. 
As stated above, here just two examples of targeted-CAs are presented, in particular 
two PET targeted CAs which are also approved for targeted radiotherapy. However, 
bioconjugation can be exploited to prepare targeted CAs also for MRI, SPECT and for 
multimodal imaging (i.e. PET/CT).119 
Moreover, other types of chelating agents can be exploited to prepare BFCAs (i.e. 
AAZTA and DTPA-like ligands) and many other vectors are suitable for the 
preparation of targeted-CAs and drugs for targeted radiotherapy (i.e. oligonucleotides, 
small molecules, metal sensors and many other).1,51,113  
 
Theranostics 
Theranostics consist in an innovative approach to the diagnosis and therapy of many 
illnesses since it exploits the same (or almost the same) molecular tool to image and 
simultaneously (or immediately after) treat the pathology. 
The target of a theranostics agent is a pathology or a pathology-associated antigen, 
for example a protein overexpressed by a tumour.  
The “take aim” of theranostics consist in a targeted-CA selective for the pathology-
associated antigen, for example a targeted PET CA. 
The magic bullet here is, instead, a targeted drug for the pathology, for example a 
radiometal complex labelled with a vector molecule selective for the pathology-
associated antigen. 
The tight succession of diagnosis and therapy and the targeted nature of theranostic 
agents have shown many clinical benefits, such as early diagnosis, higher efficacy 
and fewer side effects if compared to classical non targeted therapies.  
An example of a theranostic agent has been reported in the previous section, i.e. 
68Ga/177Lu-DOTATATE. In fact, the same vector-bound chelating agent (DOTATATE) 
can serve as both PET CA, in the form of 68Ga-complex, and as drug for targeted 
radiotherapy, in the form of 177Lu-complex. This theranostic agent is very valuable for 
neuroendocrine tumours and DOTATATE and DOTATOC metal complexes are 





and clinical studies are currently in progress. Here, the target is the somatostatin 
receptor (the pathology-associated antigen overexpressed by the tumour) and the 
magic bullet is the radiometal complex linked to a somatostatin analogue (octreotide 
or octreotate, the vector).120 
Another example of theranostic pair consist in 68Ga/177Lu PSMA-617, a theranostic 
agent currently in phase II clinical trials for the treatment of prostate cancer.119,121,122  
It consists in a 68Ga or 177Lu-complex of a DOTA-like BFCA linked through an amide 
bond to a PMSA (Prostate-specific membrane antigen) inhibitor named PMSA-617.123 
PMSA is a transmembrane protein with enzymatic activity (i.e. glutamate-preferring 
carboxypeptidase) overexpressed in prostate cancer and is the target of the 
theranostic agent 68Ga/177Lu PSMA-617.124 (Figure 1.37) 
 
 
Figure 1.37. Structure of theranostic agent 68Ga/177Lu PSMA-617.123 
 
As explained above, also here the 68Ga-complex acts as PET CA and the 177Lu-
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As thoroughly described in the first chapter, polyaminocarboxylates and 
polyaminophosphonates with mesocyclic or macrocyclic structure represent the best 
choice for the preparation of metal complexes exploited as imaging probes. These 
scaffolds ensure high thermodynamic and kinetic stability of the metal complex, 
indispensable for the application of these CAs in human.1 However, the preparation 
of these kind of chelating agents or bifunctional chelating agents is not straightforward. 
The complexity of the polyaza scaffold and of the side arms necessary to confer a 
metal complex the features listed above makes the synthetic access to these probes 
really difficult.2 
For this reason, both academia and industry are continuously searching for novel 
chelating agents and bifunctional chelating agents with a feasible and scalable 
preparation and improved feature.  
Therefore, during my PhD experience the work was articulated into three main work 
areas: 
• Regioselective protection of cyclen, 
• Synthesis of novel bifunctional chelating agents, 
• Synthesis of new chelating agents. 
The regioselective protection of cyclen is an important issue, necessary to 
functionalise this relevant scaffold with different side arms with the aim to prepare 
improved chelating agents.3 In particular, during my PhD some efforts have been 
devoted to the design and realisation of a strategy for the 1,7-heterodiprotection of 
cyclen with orthogonal protecting groups (i.e. BOC, Cbz, Alloc and formyl). This 
protection method exploits the control of pH to sequentially implant two different and 
orthogonal protecting groups in the cyclen scaffold. This strategy is very useful to 
prepare cyclen-based ligands decorated with three different side arms with improved 
features. These multifunctionalised improved ligands can serve as drugs for targeted 
radiotherapy and as probes for many imaging techniques, i.e. MRI, PET, SPECT and 







Figure 2.1. Orthogonal 1,7-heterodiprotection of cyclen.  
 
This protection method has been exploited, during my PhD, to prepare two novel 




Figure 2.2. Regioselective protection of cyclen exploited for the preparation of two 
novel BFCAs. The reactive functional group of the BFCAs is circled in green. 
 
These two novel BFCAs have been designed to prepare innovative and stable metal 
complexes conjugated with vectors such as antibody, peptides, nucleotides etc. Such 
compounds can be exploited to prepare drugs for targeted radiotherapy and CAs MRI, 
PET and SPECT.4 
 
During my PhD, the research work has been focused also on the preparation of the 
three innovative chelating agents pictured in Figure 2.3.  
 
 





TRASUTA is an innovative hexadentate mesocyclic chelating agent designed as a 
stiffened AAZTA-like ligand for gallium to be used as PET CA.4,5  
Cb-tebpm, instead, has been designed to prepare stable complexes with gadolinium 
(or in general with lanthanides) as MRI CA.6 
HB-DO3A is an HP-DO3A derivative designed to be a strong gadolinium chelator and 
a MRI CA. HB-DO3A has been thoroughly investigated in its safety profile. In vitro 
data have shown that, if compared to clinically approved MRI CAs, it presents low 
affinity to collagen, the most important biomolecule in interstitial fluids.7 This 
characteristic could confer HB-DO3A the advantage of a faster and complete 
clearance after administration to the patient, with less release of toxic gadolinium and 
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1,4,7,10-Tetraazacyclododecane (cyclen) 1 is likely the most important macrocyclic 
polyamine.1 Cyclen, apart from the coordination of metal ions in its native form, is 
employed as a building block for the synthesis of a wide variety of compounds such 
as non-viral gene vectors,2 chemical sensors,3 artificial nucleases4 and bio-imaging 
probes.5 In particular, cyclen is the starting material for the preparation of a family of 
macrocyclic ligands (e.g. DOTA6 and derivatives thereof), whose gadolinium 
complexes are currently employed in diagnostic medicine as MRI contrast agents.7 
Moreover, many bifunctional chelating agents (BFCAs), frequently applied for 
labelling peptides or antibodies with radioactive or fluorescent metal ions, are based 
on the cyclen scaffold.8 
The selective decoration of the cyclen skeleton with different substituents and 
functional groups is the first step in the preparation of the above cited derivatives. This 
is not an easy task due to the presence of four symmetrically equivalent secondary 
amines, thus several different synthetic strategies have been described so far to 
overcome the problem, most of them based on the clever use of amine protecting 
groups.9 The functionalization of a single N position may be achieved by reacting the 
appropriate electrophile with a large excess of macrocyclic compound.10 This strategy 
involves just one synthetic step and the workup is relatively simple since the excess 
of cyclen may be easily removed, but the high cost of cyclen has to be judiciously 
considered. A smaller excess of cyclen or even a 1:1 stoichiometric ratio can be used 
when the reactivity of the electrophilic reagent is suitably modulated as in the example 
of mixed p-nitrophenyl carbonates11 or N-hydroxysuccinimidyl esters.12 Multi-step 
sequences have been described to prepare mono protected cyclen, too.13 The 
complementary protection of three out of four nitrogen atoms is generally simpler, as 
mild acylating agents react slower or sometimes not at all with the fourth nitrogen 
atom. This allows the preparation in high yield of triformyl-14 and tri-BOC-cylen15, for 
example. It is worthy of mention that cyclen reacts with dimethylformamide dimethyl 
acetal (DMFDMA)16 or triethyl orthoformate17 to give an isolable orthoaminal 2, whose 
mild hydrolysis leads to the clean formation of the monoformyl derivative 3. This 





and is currently employed for the industrial production of the clinically approved MRI 
contrast agent ProHance™.18 (Figure 3.1) 
 
 
Figure 3.1. Tri/Mono-protection of cyclen 
 
Diprotected cyclen derivatives pose the additional problem of the regioselectivity, 
existing either in the 1,4- or in the 1,7- isomeric forms19 (Figure 3.2). 
 






The 1,7 di-protected pattern is easily obtained by applying the procedure reported by 
Kovacs and Sherry,20 where a careful control of pH selectively leads to the protonation 
of the two opposite nitrogen atoms, switching off their reactivity and allowing the 
introduction of two identical protecting groups (Figure 3.2). 
The easy availability of 1,7-homodiprotected derivatives of cyclen led to the use of 
these derivatives to prepare a range of functionalised chelating agents sharing an 




Figure 3.3. Homo- and hetero-diprotected cyclen and functionalised derivatives 
thereof. 
 
The potential of cyclen for hosting more elaborate substitution patterns is anyway 
higher, in fact several derivatives bearing three or even four different 
substituents/functionalities were recently reported.21 Indeed, part of the PhD research  
project, was addressed to expand this potential, focusing on the possibility to access 
1,7-hetero-diprotected cyclen derivatives. The presence of two orthogonal protecting 





substituent on the cyclen scaffold, with a specific A2BC substitution pattern 
(Figure3.3), avoiding preparations based on statistical alkylation/acylation or on the 
use of large excess of expensive macrocyclic compounds.10,22 Here an easy and 
efficient access to 1,7-heterodiprotected cyclen derivatives is reported. 
 
Results and discussion 
 
The operational simplicity of the Kovacs and Sherry procedure is especially interesting 
for preparative purposes as it works very efficiently on cyclen. The large pH gap 
between its second and third protonation steps (pKas 10.51, 9.49, 1.6, 0.8)20a allows 
one to operate on the diprotonated cyclen (Figure 3.2). Indeed, the protonation of 
cyclen, at optimal value of pH 3, occurs on opposite nitrogen atoms due to 
electrostatic repulsion of the positive charges and this can be exploited to implant two 
identical protective groups with specific 1,7 regioselectivity. Moreover, this protocol is 
scalable to large preparations, but it is limited to protective groups resistant to the 
acidic condition applied. 
The introduction of the two protecting groups in this procedure likely proceeds 
stepwise, hence the intermediate should be a monoprotected cyclen derivative, 
usually not isolated as the second introduction of the protecting group probably occurs 
quickly under the reaction conditions. This opens to the possibility of submitting a 
monoprotected cyclen to the pH conditions reported for the 1,7-difunctionalisation, 
leading to its diprotonation. In this environment, the treatment with a different acylating 
agent should lead to the introduction of a second distinct protecting group on the 
opposite nitrogen atom. 
The N-formylcyclen 3 has been selected as the starting material in consideration of 
its straightforward preparation through the literature procedure16,17 and its stability at 
pH 3. Moreover, the synthesis of 3, compared to other monoprotected cyclen 
derivatives, is shorter and characterized by a higher yield. In addition, the formyl group 
can be easily removed by either acidic or basic treatment, allowing orthogonal 





For the synthesis of the orthogonally 1,7-diprotected compounds, the appropriate 
monoprotected cyclen is dissolved in an acidified water/THF mixture (pH adjusted with 
conc. HCl, pH 3 for Cbz-Cl and Alloc-Cl, pH 5 for Boc2O). A solution of the 
correspondent acylating agent (1 - 3 eq.) in THF is then slowly added to the vigorously 
stirred mixture, the pH being maintained at the correct value by constant addition of 
sodium bicarbonate. After complete conversion of the starting material (monitored by 
TLC), the reaction mixture is extracted with petroleum ether, basified with sodium 
carbonate and extracted with dichloromethane. 
In this way, N-formylcyclen 3 was directly converted into the heterodiprotected cyclen 
derivatives 1-BOC-7-formyl (4), 1-Alloc-7-formyl (7) and 1-Cbz-7-formyl (8). In order 
to prepare other heterodiprotected cyclen derivatives and at the same time to 
demonstrate the orthogonality of the protection, the formamide group of 4 was 
selectively hydrolysed in basic conditions, leading to an alternative access to N-BOC-
cyclen 5.11,23 Reiteration of the pH-controlled derivatisation with allyl chloroformate 
yielded the mixed 1-Alloc-7-BOC (6). A similar strategy was applied to compound 8, 
whose formyl group was easily and selectively removed by acidic hydrolysis, realising 
an unprecedented preparation of N-Cbz-cyclen 9.11,12,15a,19 The latter acted as a 
preferential substrate for the pH-controlled insertion of BOC (→ 10) or Alloc group (→ 
11), respectively, completing the array of the 6 possible 1,7-heterodiprotected cyclen 
derivatives arising from the combination of 4 different protecting groups. 
All the pH-controlled reactions for the introduction of the second protecting groups 
proceeded in good yields, in the range 67%-93%, confirming the robustness of the 
protocol. It is noteworthy that no chromatographic separation is needed as no 
overreaction was observed if pH was carefully maintained in the indicated values 
(±0.3), while the acylating reagents and decomposition degradation products thereof 
were removed by extraction with petroleum ether. Furthermore, the selective removal 






Figure 3.4. (a) Boc2O, H2O/THF pH 5, RT, 10h; (b) NaOH, H2O, i-PrOH, 80°C, 40h; 
(c) Alloc-Cl, H2O/THF pH 5, RT, 5h; (d) Alloc-Cl, H2O/THF pH 3, RT, 10h; (e) Cbz-Cl, 




The preparation of six novel 1,7-heterodiprotected cyclen derivatives with all possible 





Alloc) is described for the first time. The easily accessed monoprotected N-
formylcyclen 3 is the starting material for the selective, pH-controlled introduction of 
the second different protecting group. The efficient removal of the N-formyl group 
gives an alternative access to N-BOC-cyclen and N-Cbz-cyclen and paves the way 
for the preparation of the other members of this family of 1,7-heterodiprotected 
macrocycles. Good yields are observed in the introduction of PGs, and in the selective 
removal of the formyl group. 
The synthetic protocol is easily applied and requires just a pH-meter to allow the 
preparation of these compounds; the reactions were scaled in our hands to multigram 
amounts of the substrates with no significant variation. 
In conclusion, the protocols here reported could represent a set of new useful tools in 
the hands of organic chemists to be played in the sometimes tricky game of 
multifunctional cyclen syntheses. 
Work is in progress to exploit the potential of these orthogonally protected cyclen 




Materials and methods 
Solvents and starting materials were purchased from Sigma-Aldrich or TCI Europe 
and used without further purification. All aqueous solutions were prepared from 
ultrapure laboratory grade water (18 MΩ・cm) obtained from Millipore/MilliQ 
purification system. 1H and 13C NMR spectra were recorded at 300 MHz on a Jeol 
Eclipse ECP300 spectrometer. Chemical shifts are reported in ppm with the protic 
impurities of the deuterated solvent as the internal reference. Mass spectra were 
obtained with a Thermo Finningan LCQ-Deca XP-PLUS ion trap spectrometer 
equipped with an electrospray source. High resolution mass spectra were registered 
on a ThermoScientific Q-Exactive Plus spectrometer. TLC were performed with silica 





or alkaline KMnO4. N-Monoformylcyclen 3 was prepared following the procedure 
reported in literature.16c 
 
Synthetic procedures and characterizations 
tert-Butyl 7-formyl-1,4,7,10-tetraazacyclododecane-1-carboxylate (4). A solution 
of compound 3 (1.11 g, 5.54 mmol, 1 eq), in a mixture of water (4 mL) and THF (10 
mL) is acidified to pH 5 with conc. HCl. A solution of di-tert-butyl dicarbonate (3.87 g, 
1.77 mmol, 3.2 eq) in THF (6 mL) is slowly added with vigorous stirring and the pH is 
kept at 5.0 by continuous addition of NaHCO3 during 9 h. After complete conversion 
of the substrate (monitored by TLC), the solution is extracted 3 times with petroleum 
ether. The aqueous layer is basified with Na2CO3 and extracted 3 times with CH2Cl2. 
The solvent is dried over Na2SO4 and Na2CO3, filtered and removed in vacuo to give 
compound 4 as a yellow oil (1.12 g, 67 %).  
1H NMR (300 MHz, CDCl3, 333 K) δ 7.99 (s, 1H), 3.30 – 3.14 (m, 8H), 2.85 – 2.66 (m, 
8H), 1.30 (s, 9H) ppm.  
13C NMR (75 MHz, CDCl3, 333 K) δ 164.0 (CH), 156.0 (C), 79.6 (C), 50.0 (CH2), 49.7 
(CH2), 47.5 (CH2), 45.2 (CH2), 28.4 (CH3) ppm.  
MS (ESI+): m/z = 301.11 (100%, [M+H]+), 201.28 (80%). Calc. for C14H28N4O3: 300.22.  
HRMS (ESI+): m/z = 301.22327 (100%, [M+H]+). Calc. for C14H28N4O3: 300.21614. 
 
tert-Butyl 1,4,7,10-tetraazacyclododecanecarboxylate (5). Compound 4 (1.67 g, 
3.88 mmol) is dissolved in isopropyl alcohol (10 mL), then a 1 M solution of sodium 
hydroxide in water (10 mL) is added. The reaction is heated at 80°C and the 
conversion of the substrate is monitored by TLC (CH2Cl2/MeOH/NH3 6:3.1). After 40 
h, isopropyl alcohol is removed by vacuum evaporation, and the aqueous layer is 
extracted 3 times with CH2Cl2. The solvent is dried over Na2SO4 and Na2CO3, filtered 
and removed under vacuum to give compound 5 as a yellow oil (1.01 g, 96 %).  
1H NMR (300 MHz, CDCl3, 333 K) δ 3.17 – 3.13 (m, 4H), 2.58 – 2.51 (m, 8H), 2.43 – 
2.40 (m, 5H), 1.20 (s, 9H) ppm.  
13C NMR (75 MHz, CDCl3, 333 K) δ 156.2 (C), 79.1 (C), 49.0 (CH2), 48.7 (CH2), 48.1 





MS (ESI+): m/z (100%) = 273.23 [M+H]+. Calc. for C13H28N4O2: 272.22.  
 
1-Allyl 7-tert-butyl 1,4,7,10-tetraazacyclododecane-1,7-dicarboxylate (6). A 
solution of compound 5 (0.869 g, 3.19 mmol, 1 eq) in a mixture of water (10 mL) and 
THF (8 mL) is acidified to pH 5.0 with conc. HCl. A solution of allyl chloroformate (0.37 
mL, 3.48 mmol, 1.1 eq) in THF (2 mL) is slowly added with vigorous stirring and the 
pH is maintained at 5.0 by continuous addition of NaHCO3 during 5 h. After complete 
conversion of the substrate (monitored by TLC), the solution is extracted 3 times with 
petroleum ether. The aqueous layer is basified with Na2CO3 and extracted 3 times 
with CH2Cl2. The solvent is dried over Na2SO4 and Na2CO3, filtered and removed 
under vacuum to give compound 6 as a yellow oil (0.860 g, 76 %).  
1H NMR (300 MHz, CDCl3, 333 K) δ 6.36 (br s, 2H), 5.89 – 5.76 (m, 1H), 5.21 – 5.11 
(m, 2H), 4.52 (d, J = 5.1 Hz, 2H), 3.59 – 3.50 (m, 8H), 2.92 (br s, 8H), 1.37 (s, 9H) 
ppm.  
13C NMR (75 MHz, CDCl3, 333 K) δ 156.0 (C), 155.4 (C), 132.4 (CH), 117.9 (CH2), 
80.7 (C), 66.3 (CH2), 49.6 (4 CH2), 28.3 (CH3) ppm.  
MS (ESI+): m/z = 357.12 (79%, [M+H]+), 257.27 (100%). Calc. for C17H32N4O4: 356.24.  
HRMS (ESI+): m/z = 357.24918 (100%, [M+H]+). Calc. for C17H32N4O4: 356.24236. 
 
1-Allyl 7-formyl-1,4,7,10-tetraazacyclododecane-1-carboxylate (7). A solution of 
compound 3 (1.02 g, 5.09 mmol, 1 eq) in a mixture of water (2 mL) and THF (4 mL) is 
acidified to pH 3 with conc. HCl. A solution of allyl chloroformate (1.35 mL, 12.7 mmol, 
2.5 eq) in THF (4 mL) is added with vigorous stirring over 30 min. The pH is kept at 3 
continuously adding NaHCO3 in little portion for 10 h. After complete conversion of the 
substrate (monitored by TLC, CH2Cl2/MeOH/NH3 6:3.1), the solution is extracted 3 
times with petroleum ether, the aqueous layer is basified with Na2CO3 and extracted 
3 times with CH2Cl2. The solvent is dried over Na2SO4 and Na2CO3, filtered and 
removed in vacuo to give compound 7 as a yellow oil (1.07 g, 74 %).  
1H NMR (300 MHz, CDCl3, 333 K) δ 7.70 (s, 1H), 5.57 – 5.45 (m, 1H), 4.85 (d, J = 
17.2 Hz, 1H), 4.76 (d, J = 10.4 Hz, 1H), 4.14 (s, 2H), 3.07 – 2.91 (m, 8H), 2.43 – 2.37 





13C NMR (75 MHz, CDCl3, 333 K) δ 163.2 (CH), 155.6 (C), 132.4 (CH), 116.3 (CH2), 
64.9 (CH2), 49.3 (CH2), 47.8 (CH2), 46.8 (CH2), 44.6 (CH2) ppm.  
MS (ESI+): m/z (100%) = 285.26 [M+H]+. Calc. for C13H24N4O3: 284.18. 
HRMS (ESI+): m/z = 285.19193 (100%, [M+H]+).  Calc. for C13H24N4O3: 284.18484. 
 
1-Benzyl 7-formyl-1,4,7,10-tetraazacyclododecane-1-carboxylate (8). A solution 
of compound 3 (1.98 g, 9.89 mmol, 1 eq) in a mixture of water (4mL) and THF (6 mL) 
is acidified to pH 3 with conc. HCl. A solution of benzyl chloroformate (4.2 mL, 29.7 
mmol, 3 eq) in THF (10mL) is added dropwise with vigorous stirring and the pH is 
maintained at 3 by continuous addition of NaHCO3 during for 2 h. When the pH is 
stable at 3 the solution is stirred at RT for 18 h. After complete conversion of the 
substrate (monitored by TLC, CH2Cl2/MeOH/NH3 6:3.1), the mixture is extracted 3 
times with petroleum ether, then the aqueous layer is basified with Na2CO3 and 
extracted 3 times with CH2Cl2. The solvent is dried over Na2SO4 and Na2CO3, filtered 
and removed under vacuum to give compound 8 as a yellow oil (3.06 g, 93 %).  
1H NMR (300 MHz, CDCl3, 333 K) δ 7.98 (s, 1H), 7.18 (br s, 5H), 4.98 (s, 2H), 3.27 – 
3.22 (m, 10H), 2.76 – 2.64 (m, 8H) ppm.  
13C NMR (75 MHz, CDCl3, 333 K) δ 163.8 (CH), 156.4 (C), 136.5 (C), 128.2 (CH), 
127.6 (CH), 127.5 (CH), 66.8 (CH2), 49.8 (CH2), 48.4 (CH2), 47.3 (CH2), 45.1 (CH2) 
ppm.  
MS (ESI+): m/z = 335.25 (100%, [M+H]+). Calc. for C17H26N4O3: 334.20. HRMS (ESI+): 
m/z = 335.20752 (100%, [M+H]+). Calc. for C17H26N4O3: 334.20049. 
 
Benzyl 1,4,7,10-tetraazacyclododecanecarboxylate·3HCl (9·3HCl). Compound 8 
(509 mg, 1.52 mmol) was dissolved in 1 M HCl and the solution was stirred at 50 °C 
for 20 h. The solvent was evaporated under vacuum, the residue was dissolved in 
boiling ethanol, filtrated, cooled to room temperature, and precipitated with diethyl 
ether. The product was isolated by vacuum filtration to yield compound 9·3HCl as a 
white solid (486 mg, 77%).  
1H NMR (300 MHz, D2O, 333 K) δ 7.28 (br s, 5H), 5.02 (s, 2H), 3.51 (br t, J = 4.8 Hz, 





13C NMR (75 MHz, D2O, 333 K) δ 157.9 (C), 135.4 (C), 128.6 (CH), 128.3 (CH), 128.0 
(CH), 68.3 (CH2), 45.7 (CH2), 44.9 (CH2), 43.0 (CH2), 42.6 (CH2) ppm.  
MS (ESI+): m/z (100%) = 307.22 [M+H]+. Calc. for C16H26N4O2: 306.21. 
 
1-Benzyl 7-tert-butyl 1,4,7,10-tetraazacyclododecane-1,7-dicarboxylate (10). A 
solution of compound 9 (1.44 g, 3.46 mmol, 1 eq) in a mixture of water (5 mL) and 
THF (3 mL) is acidified to pH 5 with conc. HCl. A solution of di-tert-butyl dicarbonate 
(1.51 g, 6.91 mmol, 2 eq) in THF (2 mL) is added dropwise and the pH is kept at 5 
continuously adding NaHCO3 in little portion for 10h. After complete conversion of the 
substrate (monitored by TLC, CH2Cl2/MeOH/NH3 6:3.1), the solution is extracted 3 
times with petroleum ether, the aqueous layer is basified with Na2CO3 and extracted 
3 times with CH2Cl2. The solvent is dried over Na2SO4 and Na2CO3, filtered and 
removed in vacuo to give compound 10 as a yellow oil (1.08 g, 77 %).  
1H NMR (300 MHz, CDCl3, 333 K) δ 7.05 – 7.03 (m, 5H), 4.84 (s, 2H), 3.12 – 3.04 (m, 
8H), 2.77 (br s, 2H), 2.53 (br s, 8H), 1.18 (s, 9H) ppm.  
13C NMR (75 MHz, CDCl3, 333 K) δ 156.0 (C), 155.4 (C), 136.5 (C), 127.8 (CH), 127.2 
(CH), 127.1 (CH), 78.7 (C), 66.3 (CH2), 49.6 (2 CH2), 48.3 (2 CH2), 27.9 (CH3) ppm.  
MS (ESI+): m/z = 429.15 (21%, [M+Na]+), 407.16 (100%, [M+H]+), 307.30 (23%). Calc. 
for C21H34N4O4: 406.26.  
HRMS (ESI+): m/z = 407.26487 (100%, [M+H]+). Calc. for C21H34N4O4: 406.25801. 
 
1-Allyl 7-benzyl 1,4,7,10-tetraazacyclododecane-1,7-dicarboxylate (11). A 
solution of compound 9 (1.47 g, 3.54 mmol, 1 eq), water (5 mL) and THF (3 mL) is 
acidified to pH 3 with HCl and stirred. Then a solution of allyl chloroformate (0.76 mL, 
7.08 mmol, 2 eq) and THF (2 mL) is slowly added and the pH is maintained at 3 by 
continuous addition of NaHCO3 for 10 h. After complete conversion of the substrate 
(monitored by TLC, CH2Cl2/MeOH/NH3 6:3.1), the solution is extracted 3 times with 
petroleum ether, the aqueous layer is basified with solid Na2CO3 and extracted 3 times 
with CH2Cl2. The solvent is dried over Na2SO4 and Na2CO3, filtered and removed 





1H NMR (300 MHz, CDCl3, 333 K) δ 7.04 (s, 5H), 5.68 – 5.60 (m, 1H), 4.99 (d, J = 
17.2 Hz, 1H), 4.91 – 4.85 (m, 3H), 4.31 (d, J = 2.2 Hz, 2H), 3.23 – 3.13 (m, 10H), 2.56 
(br s, 8H) ppm.  
13C NMR (75 MHz, CDCl3, 333 K) δ 155.9 (C), 155.7 (C), 136.3 (C), 132.6 (CH), 127.8 
(CH), 127.2 (CH), 127.0 (CH), 116.4 (CH2), 66.3 (CH2), 65.1 (CH2), 49.9 (2 CH2), 48.5 
(CH2), 47.9 (CH2) ppm.  
MS (ESI+): m/z (100%) = 391.27 [M+H]+. Calc. for C20H30N4O4: 390.23.  
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For this work, I have prepared and characterised all the compounds herein 












Chapter 4: Synthesis 
















Bifunctional chelating agents (BFCAs) are small molecules containing a metal 
chelating unit and a reactive functional group.1 They find widespread applications in 
chemistry, biochemistry and medicine because they can be easily conjugated to 
biomolecules, such as peptides2 or antibodies,3 and then loaded with metals or 
radiometals to obtain diagnostic, therapeutic or theranostic agents, extensively 
employed nowadays in research, preclinical and clinical studies.4  
Many popular and widely applied BFCAs are based on polyaminopolycarboxylic acids 
due to their versatility and ability to coordinate a broad variety of metal ions generating 
stable complexes.5 High thermodynamic and kinetic stabilities of metal complexes are 
usually achieved with macrocyclic chelating agents owing to the preorganized 
structure of these ligands. The typical example of this class is DOTA (Figure 4.1), 
largely exploited for the preparation of metal complexes to be used in vivo.6,7 
The macrocyclic derivatives DO3A tri-t-butyl ester 18 and DOTA(tBu)3 29 (Figure 4.1), 
both based on the 1,4,7,10-tetrazacyclododecane (“cyclen”), are among the most 
used BFCAs. Both are commercially available and can be easily prepared through 
relatively simple procedures.8-10 Compound 1 has been used in solid phase synthesis 
by derivatization of the peptide on the resin with bromoacetyl bromide (Figure 4.1, 
route a) which is then reacted with the BFCA.11 Compound 2 can be directly 
conjugated to molecules of interest bearing an amino group (e.g.: a protected peptide) 
by means of a suitable coupling agent.12 Moreover, compound 2 has been largely 
exploited in the solid phase synthesis of DOTA-functionalised peptides (Figure 4.1, 
route b).13 
There is a great interest in the design and synthesis of novel BFCAs, ranging from 








Figure 4.1. Macrocyclic BFCAs: conjugation strategies, commercially available 
examples and synthesised compounds. 
 
Here the synthesis of the novel bifunctional chelating agents 3 and 4 (Figure 4.1) is 
reported, differing from 1 and 2 by the replacement of a carboxylic moiety with a 
phosphonic group. The phosphonic group is commonly used as a (bio)isostere of 
carboxylic acid in medicinal chemistry.16 At physiological pH values the phosphonate 
tetrahedral deprotonated form (-PO32-) offers multiple coordination modes, leading to 
stabilities of the metal complexes comparable to those of the carboxylic counterpart 
or even higher.6 DO3AP (Figure 4.1) forms complexes with lanthanide (Ln3+) with 
thermodynamic stabilities higher than those of the corresponding Ln3+-DOTA 
chelates.17 Moreover, the residual anionic charges left after complexation of the 
dianionic phosphonate group provide a beneficial effect on the solvation of the 
corresponding chelate, due to the establishment of an extended hydrogen bond 
network. This is extremely important in Gd3+-complexes, currently used as MRI 
contrast agents and is clearly demonstrated in the comparison of Gd3+-DO3AP, with 
the carboxylic congener Gd3+-DOTA.18 The former, in virtue of the higher hydration of 
the paramagnetic complex shows an improved relaxivity (i.e.: contrast efficiency), 
pointing out the importance of this specific isosteric substitution of metal-coordinating 
groups. 
 
Results and discussion  
N-Formyl-cyclen 5 has been selected as the starting material for the synthesis of the 





from cyclen in almost quantitative yield.19 Compound 5 was regioselectively protected 
at position 7 by reaction with benzylchloroformate in 1,4-dioxane/water at pH 3.20 The 
regioselective protection relies on a modification of the protocol originally proposed 
by Kovacs and Sherry,21 and exploits a pH-controlled procedure for the selective 
functionalization of polyazamacrocycles. The orthogonally heterodiprotected 
derivative 6 was the key intermediate for the synthesis of both BFCAs. Alkylation of 
the secondary amines with t-butyl bromoacetate in presence of N-ethyldiisopropyl 
amine (DIPEA) as the base, followed by selective removal of the formyl protective 
group by refluxing in ethanol in presence of hydroxylamine hydrochloride, led to the 
advanced synthon 7 in 88% yield. The key phosphonic moiety was introduced 
applying a modified Kabachnik-Fields reaction,22 i.e.: treating 7 with tri-t-butyl 
phosphite and paraformaldehyde at 70°C for 36 h.23 The resulting protected mixed 
phosphonic-carboxylic ester was not isolated due to observed instability. The Cbz 
protective group was directly and easily removed by hydrogenolysis (Pd/C in 
methanol), obtaining the monophosphonic DO2AP tetra-t-butyl ester 3 in 65% yield 
over two steps.  
The second BFCA bears an additional side arm containing the free carboxylic acting 
as the remote reactive functional group. The side arm is introduced by alkylation of 
the secondary amine 3 with benzyl bromoacetate in acetonitrile at room temperature 
in the presence of K2CO3 as the base. Selective removal of the benzyl ester by 
catalytic hydrogenolysis completes the preparation of the desired bifunctional 
chelating agent 4 (DO3AP(tBu)4, Figure 4.2). 
 
 










In summary, a concise entry to two macrocyclic bifunctional chelating agents, formally 
derived from the widely used DOTA/DO3A ligands, has been described in this work. 
The synthesis of the two new BFCAs starts from a readily available mono-protected 
cyclen and involves simple steps, requiring common and low-price reagents and 
exploiting a recently reported and very effective protection method.20 Future 
development of this work will deal with the conjugation of the two new BFCAs to 
molecular vectors and evaluation of the corresponding conjugated metal complexes 




Materials and methods 
Reagent-grade chemicals and solvents were obtained from commercial sources and 
directly used without further purification. All aqueous solutions were prepared from 
ultrapure laboratory grade water (18 MΩ∙cm) obtained from Millipore/MilliQ purification 
system. 1-Formyl-1,4,7,10-tetrazacyclododecane19a,19b and tri-t-butyl phosphite23 
were synthesized as reported in the literature. TLC was performed on Merck silica gel 
60 TLC plates F254 and visualized by using UV or spraying with 1% KMnO4 in 1 M 
NaOH or Dragendorff reagent. Flash chromatography was carried out on Merck silica 
gel 60 (230-400 mesh). The 1H, 13C, and 31P spectra were recorded on a Bruker 
Avance 400 instrument or on a Jeol Eclipse ECP 300 MHz. Chemical shifts are 
reported in ppm with the protic impurities of the deuterated solvent as the internal 
reference. 31P spectra were recorded using phosphoric acid (85 wt. % solution in 
water) as an external standard. Mass spectra were recorded with a Thermo Finnigan 
TSQ700 triple-quadrupole instrument or with a Thermo Finnigan LCQ-Deca XP-PLUS 





resolution mass spectra were registered on a ThermoScientific Q-Exactive Plus 
spectrometer. IR spectra were collected by a Bruker Alpha II instrument or by a 
Thermo Nicolet AVATAR 370 FT-IR. 
 
Synthetic procedures and characterizations 
7-Formyl-1,4,7,10-tetraazacyclododecane-1-carboxylic acid benzyl ester 
dihydrochloride (6) 
1-Formyl-1,4,7,10-tetrazacyclododecane 5 (14 g, 69.9 mmol, 1.0 equiv) was dissolved 
in water (100 mL) and 12 N HCl was added until pH 3. 1,4-Dioxane (220 mL) was 
added and then a solution of benzyl chloroformate (13.8 g, 77 mmol, 1.1 equiv) in 1,4-
dioxane (15 mL) was slowly added dropwise in 3.5 h while the pH of the mixture was 
constantly maintained at pH 3 by continuous addition of 2 N NaOH with a pHstat 
apparatus. When the addition was completed, the reaction mixture was stirred again 
for 1 h then extracted with n-hexane (4x100 mL) and diisopropyl ether (4x100 mL). 
The pH of the aqueous phase was raised to 13 by addition of 10N NaOH and extracted 
with CHCl3 (4x100 mL). The organic phase was washed with brine (100 mL), dried 
(Na2SO4), filtered and evaporated. The oily residue was dissolved in acetone (200 
mL) and 6 N HCl (26 mL) was added. The solid precipitated was filtered, washed with 
acetone (2x50 mL) and dried under vacuum to give compound 6 (23.6 g, 83 %) as a 
white solid.  
M.p. > 200 °C.  
Argentometric titer (0.1N AgNO3): 98%.  
IR (neat): 3449, 2931,1695, 1654, 1413, 1220, 1143, 1019, 701 cm–1.  
1H NMR (400 MHz, D2O, 298 K) δ 8.13 (s, 1H), 7.38 – 7.33 (m, 5H), 5.09 (s, 2H), 3.72 
– 3.71 (m, 2H), 3.65 (br s, 2H), 3.59 – 3.56 (m, 4H), 3.37 – 3.29 (m, 8H) ppm.  
13C NMR (100 MHz, D2O, 298 K) δ 169.1 (CH), 159.2 (C), 136.0 (C), 129.3 (CH), 
129.2 (CH), 128.9 (CH), 69.0 (CH2), 47.5 (2 CH2), 47.3 (CH2), 46.7 (CH2), 45.7 (CH2), 
45.5 (CH2), 44.9 (CH2), 42.3 (CH2) ppm.  
MS (ESI+): m/z = 335.25 (100%, [M+H]+). Calc. for C17H26N4O3: 334.20.  
Anal. Calcd for C17H28N4Cl2O3: C, 50.13; H, 6.93; N, 13.75; Cl, 17.41. Found: C, 50.29; 






4-Benzyloxycarbonyl-1,4,7,10-tetrazacyclododecane-1,7-diacetic acid di-t-butyl 
ester (7) 
A solution of compound 6 (14.4 g, 35.3 mmol, 1.0 equiv) and 1 N NaOH (74 mL, 74 
mmol, 2.1 equiv) in water (450 mL) was stirred for 20 min then extracted with CHCl3 
(4x200 mL). The organic phase was separated and evaporated. The oily residue was 
dissolved in acetonitrile (180 mL) and N-ethyldiisopropylamine (15 mL) was added. A 
solution of t-butyl bromoacetate (16.8 g, 86.1 mmol, 2.4 equiv) in acetonitrile (15 mL) 
was slowly added in 2.5 h. The reaction mixture was stirred at room temperature for 
20 h and then evaporated. The oily residue was dissolved in CHCl3 (150 mL) and the 
solution washed with water (5x100 mL). The organic phase was dried (Na2SO4), 
filtered and evaporated. The residue was dissolved in EtOH (250 mL) and 
hydroxylamine hydrochloride (2.93 g, 42.2 mmol) was added. The reaction mixture 
was refluxed for 48 h then evaporated. The residue was dissolved in CH2Cl2 (250 mL), 
the solution washed with water (3x250 mL) then with brine (3x250 mL). The organic 
phase was dried (Na2SO4), filtered and evaporated. The oily residue was purified by 
flash chromatography (CHCl3/MeOH = 9:1, Rf: 0.32). The glassy white solid obtained 
was dissolved in water (600 mL) and 1 N NaOH (90 mL) and extracted with CHCl3 
(3x250 mL). The organic phases were pooled, dried (Na2SO4) and evaporated to give 
compound 7 (16.6 g, 88%) as an oil.  
IR (NaCl): 3304, 2978, 2933, 1724, 1702, 1497, 1393, 1115, 754 cm–1.  
1H NMR (400 MHz, CDCl3, 298 K) δ 7.33 – 7.28 (m, 5H), 5.10 (s, 2H), 3.46 – 3.44 (m, 
4H), 3.29 (br s, 5H), 2.84 – 2.79 (m, 8H), 2.67 – 2.65 (m, 4H), 1.42 (s, 18H) ppm.  
13C NMR (100 MHz, CDCl3, 298 K) δ 171.0 (C), 157.3 (C), 137.1 (C), 128.9 (CH), 
128.4 (CH), 128.3 (CH), 81.3 (C), 67.5 (CH2), 55.7 (CH2), 53.0 (CH2), 51.9 (CH2), 48.7 
(CH2), 44.8 (CH2), 28.6 (CH3), ppm.  
MS (ESI+): m/z = 535.4 (100%, [M+H]+), 479.3 (56%), 423.0 (30%). Calc. for 
C28H46N4O6: 534.3.  








acid di-t-butyl ester (3) 
A mixture of compound 7 (13.9 g, 26 mmol, 1 equiv), tri-t-butyl phosphite (7.6 g, 28.6 
mmol, 1.1 equiv) and paraformaldehyde (0.9 g, 30 mmol, 1.15 equiv) was stirred and 
heated at 70 °C. After 16 h, additional tri-t-butyl phosphite (1 g, 3.8 mmol, 0.15 equiv) 
and paraformaldehyde (0.1 g, 3.3 mmol, 0.13 equiv) were added and the mixture was 
heated for further 20 h. The mixture was evaporated under vacuum at 80°C to 
eliminate volatile by-products. The oily residue was dissolved in methanol (145 mL), 
5% Pd/C (2.6 g) was added and the mixture was stirred under hydrogen atmosphere 
at room temperature for 8 h. The mixture was filtered through a Millipore FT 0.45 μm 
filter, evaporated and the residue was purified by flash chromatography (CH2Cl2 then 
CH2Cl2/MeOH = 9:1) to give compound 3 (10.3 g, 65% over two steps) as a brown oil.  
IR (neat): 2977, 2927, 1730, 1368, 1223, 1152, 973, 917, 849, 692 cm–1.  
1H NMR (300 MHz, CDCl3, 333 K) δ 3.02 – 2.91 (m, 5H), 2.71 – 2.38 (m, 18H), 1.09 
(s, 18H), 1.04 (s, 18H) ppm.  
13C NMR (75 MHz, CDCl3, 333 K) δ 169.8 (C), 82.2 (C, d, J = 9.8 Hz), 80.6 (C), 57.5 
(CH2), 51.2 (CH2), 50.9 (CH2), 48.9 (CH2), 46.8 (CH2), 45.3 (CH2, d, J = 145 Hz), 29.9 
(CH3, d, J = 3.7 Hz), 27.5 (CH3) ppm.  
31P NMR (121 MHz, CDCl3, 333 K): δ = 18.1 (s) ppm.  
MS (ESI+): m/z = 607.24 (100%, [M+H]+), 551.20 (21%), 495.16 (35%), 439.15 (34%), 
383.18 (20%). Calc. for C29H59N4O7P: 606.41.  
HRMS (ESI+): m/z = 607.41886 (100%, [M+H]+), 629.40094 (46%, [M+Na]+).  Calc. 
for C29H59N4O7P: 606.41214. 
 
7-[[Di(t-butoxy)phosphoryl]methyl]-1,4,7,10-tetrazacyclododecane -1,4,10-
triacetic acid 1-benzyl 4,10-di-t-butyl ester (8) 
Benzyl bromoacetate (1.4 g, 6.26 mmol, 2 equiv) was added dropwise in 1 h to a 
suspension of compound 3 (1.9 g, 3.13 mmol, 1 equiv), potassium carbonate (1.3 g, 
9.39 mmol, 3 eq) and acetonitrile (10 mL). The mixture was stirred at room 
temperature for 36 h then evaporated. The residue was purified by flash 






IR (neat): 2979, 2921, 1730, 1688, 1370, 1156, 980, 800, 730, 697 cm–1.  
1H NMR (300 MHz, CD3OD, 313 K) δ 7.36 (s, 5H), 5.20 (s, 2H), 3.34 – 3.25 (m, 6H), 
3.00 (d, J = 10.3 Hz, 2H), 2.77 – 2.39 (m, 16H), 1.54 (s, 18H), 1.48 (s, 18H) ppm.  
13C NMR (75 MHz, CD3OD, 298 K) δ 175.2 (C), 174.3 (C), 137.0 (C), 129.7 (CH), 
129.5 (CH), 129.4 (CH), 85.0 (C, d, J = 9.9 Hz), 83.3 (C), 67.9 (CH2), 57.6 (8 CH2), 
56.4 (3 CH2), 54.3 (CH2, d, J = 151.5 Hz), 31.0 (CH3, d, J = 3.5 Hz), 28.5 (CH3).  
31P NMR (121 MHz, CD3OD, 313 K): δ = 19.7 (s) ppm.  
MS (ESI+): m/z = 777.5 (100%, [M+Na]+), 721.4 (15%). Calc. for C38H67N4O9P: 754.5.  
 
7-[[Di(t-butoxy)phosphoryl]methyl]-1,4,7,10-tetrazacyclododecane-1,4,10-
triacetic acid 4,10-di-t-butyl ester (4) 
A mixture of compound 8 (1.38 g, 1.83 mmol), 10% Pd/C (0.28 g) and MeOH (10 mL) 
was stirred under hydrogen atmosphere at room temperature for 10 h. The mixture 
was filtered through Celite and evaporated to give compound 4 (1.20 g, 99%) as a 
pale-yellow oil.  
IR (neat): 3381, 2975, 1725, 1650, 1367, 1151, 1070, 976, 567, 433 cm–1. 
1H NMR (300 MHz, CD3OD, 313 K) δ 3.79 – 2.82 (m, 24H), 1.52 – 1.48 (m, 36H) ppm.  
13C NMR (75 MHz, CD3OD, 298 K) δ 170.9 (C), 169.1 (C), 82.7 (C), 79.9 (C, d, J = 
8.1 Hz), 57.4 (CH2), 54.2 (CH2), 52.4 (CH2, d, J = 140.6 Hz), 52.3 (CH2), 51.8 (6 CH2), 
30.1 (CH3, d, J = 3.8 Hz), 27.6 (CH3) ppm.   
31P NMR (121 MHz, CD3OD, 313 K): δ 5.85 (s).  
MS (ESI+): m/z = 703.2 (36%, [M+K]+), 687.4 (100%, [M+Na]+), 630.9 (12%). Calc. for 
C31H61N4O9P: 664.4.  
HRMS (ESI+): m/z = 665.42279 (100%, [M+H]+), 687.40452 (55%, [M+Na]+). Calc. for 
C31H61N4O9P: 664.41762.  
 
References 
(1) For representative reviews see: (a) Sarko, D.; Eisenhut, M.; Haberkorn, U.; Mier, 
W. Curr. Med. Chem. 2012, 19, 2667. (b) Liu, S. Adv. Drug Deliv. Rev. 2008, 
60, 1347. (c) Liu, S. Chem. Soc. Rev. 2004, 33, 445. (d) Kostelnik, T. I.; Orvig, 





(2) (a) Jackson, J. A.; Hungnes, I. N.; Ma, M. T.; Rivas, C. Bioconjugate Chem. 
2020, 31, 483. (b) Jamous, M.; Haberkorn, U.; Mier, W. Molecules 2013, 18, 
3379. (c) Fani, M.; Maecke, H. R.; Okarvi, S. M. Theranostics 2012, 2, 481. (d) 
De León-Rodríguez, L. M.; Kovacs, Z. Bioconjugate Chem. 2008, 19, 391. (e) 
Fichna, J.; Janecka, A. Bioconjugate Chem. 2003, 14, 3. 
(3) (a) Steiner, M.; Neri, D. Clin. Cancer Res. 2011, 17, 6406. (b) Boswell, C. A.; 
Brechbiel, M. W. Nucl. Med. Biol. 2007, 34, 757. (c) Milenic, D. E.; Brady, E. D.; 
Brechbiel, M. W. Nat. Rev. Drug Discov. 2004, 3, 488. (d) Larson, S. M.; 
Carrasquillo, J. A.; Cheung, N.-K. V.; Press, O. W. Nat. Rev. Cancer 2015, 15, 
347. 
(4) For representative reviews see: (a) Banerjee, S.; Pillai, M. R. A.; Knapp, F. F. 
Chem. Rev. 2015, 115, 2934. (b) Price, E. W.; Orvig, C. Chem. Soc. Rev. 2014, 
43, 260. (c) Ramogida, C. F.; Orvig, C. Chem. Commun. 2013, 49, 4720. (d) 
Bartholomä, M. D. Inorg. Chim. Acta 2012, 389, 36. (e) Frullano, L.; Caravan, 
P. Curr. Org. Synth. 2011, 8, 535. (f) Bhattacharyya, S.; Dixit, M. Dalton Trans. 
2011, 40, 6112. 
(5) (a) Giovenzana, G. B.; Lattuada, L.; Negri, R. Isr. J. Chem. 2017, 57, 825. (b) 
Lattuada, L.; Barge, A.; Cravotto, G.; Giovenzana, G. B.; Tei, L. Chem. Soc. 
Rev. 2011, 40, 3019. 
(6) (a) Wahsner, J.; Gale, E. M.; Rodríguez-Rodríguez, A.; Caravan, P. Chem. Rev. 
2019, 119, 957. (b) Hermann, P.; Kotek, J.; Kubíček, V.; Lukeš, I. Dalton Trans. 
2008, 3027. (c) Stasiuk, G. J.; Long, N. J. Chem. Commun. 2013, 49, 2732. 
(7) Bianchi, A.; Calabi, L.; Corana, F.; Fontana, S.; Losi, P.; Maiocchi, A.; Paleari, 
L.; Valtancoli, B. Coord. Chem. Rev. 2000, 204, 309. 
(8) Moore, D. A. Org. Synth. 2008, 85, 10. 
(9) Heppeler, A.; Froidevaux, S.; Mäcke, H. R.; Jermann, E.; Béhé, M.; Powell, P.; 
Hennig, M. Chem. Eur. J. 1999, 5, 1974. 
(10) (a) Jagadish, B.; Brickert-Albrecht, G. L.; Nichol, G. S.; Mash, E. A.; Raghunand, 
N. Tetrahedron Lett. 2011, 52, 2058. (b) Li, C.; Winnard, P.; Bhujwalla, Z. M. 
Tetrahedron Lett. 2009, 50, 2929. (c) Oliver, M.; Jorgensen, M. R.; Miller, A. D. 





Y.; Uehara, T.; Ogawa, K.; Konishi, J.; Saji, H. J. Pharm. Pharmacol. 2002, 54, 
1073. 
(11) Varshney, R.; Hazari, P. P.; Uppal, J. K.; Pal, S.; Stromberg, R.; Allard, M.; 
Mishra, A. K. Cancer Biol. Ther. 2011, 11, 893. 
(12) (a) Marsouvanidis, P. J.; Nock, B. A.; Hajjaj, B.; Fehrentz, J.-A.; Brunel, L.; 
M’Kadmi, C.; van der Graaf, L.; Krenning, E. P.; Maina, T.; Martinez, J.; de Jong, 
M. J. Med. Chem. 2013, 56, 2374. (b) Manzoni, L.; Belvisi, L.; Arosio, D.; 
Bartolomeo, M. P.; Bianchi, A.; Brioschi, C.; Buonsanti, F.; Cabella, C.; 
Casagrande, C.; Civera, M.; De Matteo, M.; Fugazza, L.; Lattuada, L.; Maisano, 
F.; Miragoli, L.; Neira, C.; Pilkington‐Miksa, M.; Scolastico, C. ChemMedChem 
2012, 7, 1084. (c) Wardle, N. J.; Kalber, T.; Bell, J. D.; Bligh, S. W. A. Bioorg. 
Med. Chem. Lett. 2011, 21, 3346. 
(13) (a) Azad, B. B.; Rota, V. A.; Breadner, D.; Dhanvantari, S.; Luyt, L. G. Bioorg. 
Med. Chem. 2010, 18, 1265. (b) Mishra, R.; Su, W.; Pohmann, R.; Pfeuffer, J.; 
Sauer, M. G.; Ugurbil, K.; Engelmann, J. Bioconjugate Chem. 2009, 20, 1860. 
(c) Sosabowski, J. K.; Mather, S. J. Nat. Protoc. 2006, 1, 972. (d) De León-
Rodríguez, L. M.; Ortiz, A.; Weiner, A. L.; Zhang, S.; Kovacs, Z.; Kodadek, T.; 
Sherry, A. D. J. Am. Chem. Soc. 2002, 124, 3514. (e) Graham, K. A. N.; Wang, 
Q.; Eisenhut, M.; Haberkorn, U.; Mier, W. Tetrahedron Lett. 2002, 43, 5021. 
(14) Minazzi, P.; Lattuada, L.; Menegotto, I. G.; Giovenzana, G. B. Org. Biomol. 
Chem. 2014, 12, 6915. 
(15) (a) Giovenzana, G. B.; Guanci, C.; Demattio, S.; Lattuada, L.; Vincenzi, V. 
Tetrahedron 2014, 70, 4809. (b) Barge, A.; Cappelletti, E.; Cravotto, G.; 
Ferrigato, A.; Lattuada, L.; Marinoni, F.; Tei, L. Org. Biomol. Chem. 2009, 7, 
3810. (c) Anelli, P. L.; Lattuada, L.; Gabellini, M.; Recanati, P. Bioconjugate 
Chem. 2001, 12, 1081. (d) Anelli, P. L.; Fedeli, F.; Gazzotti, O.; Lattuada, L.; 
Lux, G.; Rebasti, F. Bioconjugate Chem. 1999, 10, 137. (e) Lattuada, L.; 
Gabellini, M. Synth. Commun. 2005, 35, 2409. 
(16) (a) Ballatore, C.; Huryn, D. M.; Smith, A. B. ChemMedChem 2013, 8, 385. (b) 
Patani, G. A.; LaVoie, E. J. Chem. Rev. 1996, 96, 3147. 
(17) Táborský P., Lubal P., Havel J., Kotek J., Hermann P., Lukeš I. Collect. Czech. 





(18) Rudovský J., Cígler P., Kotek J., Hermann P., Vojtíšek P., Lukeš I., Peters J. A., 
Elst L. V., Muller R. N. Chem. Eur. J. 2005, 11, 2373. 
(19) (a) Ferrand, A.-C.; Imbert, D.; Chauvin, A.-S., Vandevyver, C. D. B.; Bünzli, J.-
C. G. Chem. Eur. J. 2007, 13, 8678. (b) Dischino, D. D.; Delaney, E. J.; 
Emswiler, J. E.; Gaughan, G. T.; Prasad, J. S.; Srivastava, S. K.; Tweedle, M. 
F. Inorg. Chem. 1991, 30, 1265. 
(20) Travagin, F.; Lattuada, L.; Giovenzana, G. B. Org. Chem. Front. 2019, 6, 1387. 
(21) Kovacs, Z.; Sherry, A. D. Synthesis 1997, 759. 
(22) Keglevich, G.; Bálint, E.; Kangyal, R.; Bálint, M.; Milen, M. Heteroatom Chem. 
2014, 25, 282. 
(23) Manning, H. C.; Bai, M.; Anderson, B. M.; Lisiak, R.; Samuelson, L. E.; Bornhop, 
D. J. Tetrahedron Lett. 2005, 46, 4707. 
(24) Lattuada, L.; Cappelletti, E.; Linder, K. E.; Nunn, A. D. United States Patent 
US20110250133A1, 2011.  
(25) Lattuada, L.; Napolitano, R.; Boi, V.; Visigalli, M.; Aime, S.; Giovenzana, G. B.; 
Mingo, A. F. World Intellectual Property Organization WO2017178301A1, 2017. 
 
Adapted from Synlett, 2020, 31(13), 1291-1294 with permission from Georg Thieme 
Verlag. 
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Chapter 5: TRASUTA, 
a new hexadentate 
spirocyclic chelator 
for gallium-based 











PET (positron emission tomography) is an essential tool in oncology since it is able to 
highlight the finest changes in the body at a molecular level. PET exploits 
radionuclides that, properly introduced in a molecular entity and administered to the 
patient, distribute themselves in the whole body or in specific anatomic regions. Once 
there, each of them emit positrons, which annihilate due to the contact with electrons 
of the living matter generating two collinear γ rays. These are subsequently captured 
by a gamma camera and a computer reconstruct the origin of the radiations 
generating 3D images.1,2 
In the literature many different radiolabelled nanoparticles3,4 and biomolecules are 
reported and some of them are clinically approved, such as fludeoxyglucose (18F)5, 
fluorodopa (18F)6, choline (11C)5 etc. (Figure 5.1) 
 
 
Figure 5.1. Fluorodopa (18F), choline (11C), clinically approved PET contrast 
agents. 
 
These compounds are very useful since they can trace fine physio-pathological 
changes in the body thanks to their biobased structures.1,2 However, the introduction 
of a newly synthesised radioisotope (such as 18F or 11C) in a non-radioactive precursor 
is not an easy task. In fact, this kind of labelling exploits classical organic chemistry 
procedures, with all their limitations, such as incomplete conversion, need for 
purification, long reaction times etc. Moreover, these matters are complicated by the 
issues deriving from the short half-life values of 18F or 11C, which entangle the 





For this reason, in the recent years, radiometal complexes have made their 
appearance into the field of PET contrast agents. Radionuclides, such as 68Ga, 64Cu, 
111In, 89Zr and 44Sc, possess favourable half-life values for β+ decay. 2,7  
In particular, 68Ga has found the more widespread clinical application because it 
possesses interesting decaying features, very compatible for PET imaging purposes. 
68Ga, in fact, has a half-life of 68 min and decays to 68Zn by β+ emission. 68Ga is 
produced from 68Ge by a dedicated generator, recently become an inexpensive 
technology, affordable for hospitals. 68Ge is long-lived (271 days) and it decays by 
electron capture to 68Ga3+, which is then purified by cation-exchange 
chromatography.8,9  
The synthesis of radiometal complexes requires one simple step, the complexation 
reactions, which usually proceeds spontaneously in solution with excellent yields. 
Since the short half-life values of the above mentioned radiometals, ligands with a 
quick complexation kinetic are preferable. However, long decomplexation kinetics and 
thermodynamic stability of complexes are also important to ensure that the complex 
does not release the metal in the body, generating side effects and loss of imaging 
selectivity. These characteristics are important for many applications of chelating 
agents and metal complexes, but sometimes are not very easy to tune.1,2,7,8  
In fact, chelating agents may be divided into two main classes of compounds, linear 
and macrocyclic.  
Linear chelating agents were the first CAs approved for clinical use, their preparation 
is straightforward and their complexes are rapidly formed, but at the same time they 
are thermodynamically and kinetically less stable, leading to toxic effects in vivo. Due 
to these significant disadvantages, the clinical relevance of linear CAs is fading away.  
On the contrary, the synthesis of macrocyclic ligands is tougher, but in exchange their 
complexes possess a great kinetic and thermodynamic stability, though they are 
slowly formed.10  
This category of chelating agents has found widespread applications in the field of 
PET chelating agents, which culminated in the recent clinical approval of DOTATOC. 
The latter is a radiopharmaceutical developed for the functional imaging of 





to the vector molecule octreotide, a somatostatin analogue and complexed with 
gallium.11 
However, DOTA-like ligands require long reaction times, high radiometal 
concentrations and high temperatures (70 – 95 °C) which sometimes are not 
compatible with vector biomolecules.7 
Instead, the innovative class of mesocyclic ligands, owns intermediate characteristics 
between the two previously listed ones. Their synthesis is relatively accessible and 
inexpensive, and their complexes show good kinetic and thermodynamic stability 
combined with a rapid kinetic of formation.10  
AAZTA is a representative heptadentate polyaminocarboxylic mesocyclic ligand 
showing competitive and complementary complexing behaviour compared to both 
linear and macrocyclic CAs.12,13 (Figure 5.2) 
 
 
Figure 5.2. BOPTA (linear CA), AAZTA (mesocyclic CA) and PCTA (macrocyclic CA). 
  
In fact, AAZTA form very stable complexes with post-transition metals and with block 





Because of these valuable features, a vast number of AAZTA derivatives have been 
synthesised and reported in literature, in the last two decades, in order to improve the 
metal chelates stability, efficacy and selectivity in their use as CAs.12  
AAZTA-like bifunctional chelating agents (BFCAs) have been reported as well to 
conjugate imaging-related metals to diagnostic-relevant biomolecules, exploiting the 
advantageous structure of AAZTA.14–16 
AAZTA and its derivatives have been also complexed with gallium to evaluate their 
possible use as PET contrast agents.17–19 For example, Ga-AAZTA-MG consists in an 
AAZTA-like BFCA (AAZTA-C9) linked to minigastrin, a peptide which targets 
cholecystokinin receptors and is really useful in PET imaging of neuroendocrine 
tumours.20,21 
Moreover, many AAZTA derivatives, in which the mesocyclic structure is modified are 
reported in the literature. Some of them exploit a very common method to modulate 
metal complexes characteristics, i.e. to rigidify the structure of the ligand. For 
example, fusion of the mesocycle with an additional ring reduces the degrees of 
freedom and the number of conformations of the resulting structure. Therefore, it is 
more difficult for the metal to escape from the complex. 
In the literature two different successful approaches to make rigid bicyclic AAZTA 
derivatives are reported to date.22 
Approach #1 (Figure 5.3) involves the fusion of six-membered ring with positions 2 – 
3 of the 7-membered diazepane ring leading to “CyAAZTA”23. Approach #2 generates 
the alternative “PIDAZTA”, bearing the new six-membered ring implanted on atoms 1 
and 2.22  
The present work, conversely, is focused on the original preparation of an AAZTA 
derivative (“TRASUTA”) with a five-membered ring between position 6 and the 







Figure 5.3. Different strategies to make AAZTA more rigid. 
 
To evaluate if TRASUTA could be suitable as gallium chelating agent we have 
performed a complete array of potentiometric titrations to determine the stability 
constants of Ga-TRASUTA complex. These measurements are preliminary to a 
possible exploitation of TRASUTA as a novel PET contrast agent.   
 
Results and discussion 
The synthesis of TRASUTA (2,2',2''-(1,7,10-triazaspiro[4.6]undecane-1,7,10-
triyl)triacetic acid) (Figure 5.4) implies an initial nitro-Mannich reaction between the 
commercial and inexpensive benzathine 1, nitromethane and aqueous formaldehyde 
in refluxing ethanol to produce intermediate 2 in almost quantitative yield. Then, 
compound 2 is treated with potassium tert-butoxide in dry tetrahydrofuran at room 
temperature for 30 minutes with vigorous stirring. Methyl acrylate is slowly added to 
the mixture, then left at room temperature for 3 hours. Intermediate 3 is obtained in 
95% yield over 2 steps and, in the following step, it is reduced under hydrogen 
atmosphere in the presence of Raney Nickel as a catalyst in methanol at room 





is refluxed for another 20 hours to complete the cyclization reaction to compound 4 
which crystallise from ethyl acetate in 52% yield (Procedure 4A). Intermediate 4 is 
treated with lithium aluminium hydride in refluxing THF for 24 h under nitrogen 
atmosphere obtaining compound 5 in almost quantitative yield. Intermediate 5 is then 
reduced under hydrogen atmosphere in the presence of Pd/C as a catalyst in 
methanol at room temperature for 28 hours quantitatively yielding compound 6. The 
latter is alkylated with tert-butyl bromoacetate in acetonitrile using potassium 
carbonate as base leading to the formation of compound 7 in 31% yield (Procedure 
7A). The final step requires the treatment of intermediate 7 with trifluoroacetic acid at 
room temperature for 28 h achieving the desired product TRASUTA in 73 % yield 
(Figure 5.4). 
Analysing the synthetic strategy employed, it is evident that the third and the sixth 
steps are the bottlenecks of the entire synthetic process, therefore some efforts have 







Figure 5.4. Synthesis of TRASUTA. 
 
Precisely, in the third step, alternative reducing methodologies, such as iron 





dissolving-metal reduction with iron in refluxing acetic acid for 20 h performed quite 
well, the yield (49%) was similar to the Raney Nickel procedure (52%) but quenching 
and work-up were plagued by low recovery of the product (Procedure 4B). Zinc in 
refluxing acetic acid for 20 h, was the worst combination with a very low isolated yield 
(15%) (Procedure 4C). 
The sixth step of TRASUTA synthesis, involving an alkylation reaction with tert-butyl 
bromoacetate, did not reach satisfying yields. Different combination of solvents, bases 
and temperatures were tested, with the higher results being a meagre 31% yield, 
nevertheless useful to accumulate enough material for our purposes (Procedures 7A 
– 7C).  
The determination of pKa values of TRASUTA was performed by potentiometric 







Table 5.1. pKa values of TRASUTA. 
 
The preparation of the gallium complex (Figure 5.5) was straightforward, considering 
instantaneous the reaction of stoichiometric amounts of TRASUTA with the 







Figure 5.5. Ga3+-TRASUTA 
 
Stability and protonation constants of Ga(III)-complexes formed with TRASUTA were 
determined by potentiometric titration of 1:1 metal/TRASUTA mixtures in the pH range 
2 - 12 in a 0.15 M NaCl solution at 298 K. The stability constants of TRASUTA are 







Table 5.2. Stability constants of Ga3+-TRASUTA. 
 
The species distribution of Ga3+-TRASUTA system ([Ga3+] = [TRASUTA] = 1.0 mM, 







Figure 5.6. Species distribution of Ga3+-TRASUTA system. 
 
Conclusions 
In this section an unprecedented hexadentate spirocyclic chelating agent has been 
presented, discussing in detail its synthesis, the characterization of its acid-base 
behaviour and the stability of its gallium complex. This analysis represents a 
preliminary assessment of TRASUTA as a Ga3+ chelator to evaluate its possible 
application as PET contrast agent. 
Future developments will concern the optimisation of TRASUTA synthesis, such as 
reaction conditions, overall yield and purification process. Moreover, we will evaluate 
the complexometric behaviour of TRASUTA with other metal ions of diagnostic and 












Materials and methods 
Solvents and starting materials were purchased from Merck or TCI and used without 
further purification. All aqueous solutions were prepared from ultrapure laboratory 
grade water (18 MΩ・cm) obtained from Millipore/MilliQ purification system. 1H and 
13C NMR spectra were recorded at 300 MHz on a Jeol Eclipse ECP300 spectrometer. 
Chemical shifts are reported in ppm with the protic impurities of the deuterated solvent 
as the internal reference. Mass spectra were obtained with a Thermo Finningan LCQ-
Deca XP-PLUS ion trap spectrometer equipped with an electrospray source. TLC 
were performed with silica gel (MN Kieselgel 60F254) and visualized by UV or sprayed 
with Dragendorff reagent or alkaline KMnO4. Column chromatography was carried out 




N,N’-dibenzylethylendiamine (freshly obtained by extraction with DCM of a NaOH 
aqueous solution of N,N’-dibenzylethylendiamine diacetate, 29.6 g, 82.0 mmol) and 
nitromethane (4.4 mL, 82.0 mmol) were dissolved in ethanol (100 mL). Formaldehyde 
solution (37 wt. % in water, 26.6 g, 354 mmol) was added in small portions under 
stirring, and the suspension was heated to reflux for 5 h. The reaction mixture was 
evaporated in vacuo, and the crude product was dissolved in basified water (NaHCO3) 
and extracted three times with ethyl acetate. The organic phase was then dried over 
Na2CO3 and Na2SO4, filtered and evaporated. The waxy residue was purified on silica 
gel chromatography column (DCM) to give compound 2 as a brown oil (28.6 g, 98 %). 
1H NMR (300 MHz, CDCl3, 298 K) δ 7.39 – 7.30 (m, 10H), 3.77 – 3.63 (m, 6H), 3.54 
(d, J = 14.4 Hz, 2H), 3.06 (d, J = 14.3 Hz, 2H), 2.73 – 2.58 (m, 4H), 2.33 (br s, 1H) 
ppm. 
13C NMR (75 MHz, CDCl3, 298 K) δ 138.8 (C), 129.0 (CH), 128.4 (CH), 127.4 (CH), 





MS (ESI+): m/z = 356.20 (100%, [M+H]+). Calc. for C20H25N3O3: 355.19. 
 
Methyl 3-(1,4-dibenzyl-6-nitro-1,4-diazepan-6-yl)propanoate (3) 
Compound 2 (20 g, 56,3 mmol) was dissolved in anhydrous THF (148 mL), potassium 
tert-butoxide (9.47 g, 84.4 mmol) was added and the suspension was stirred at RT for 
30 min. Methyl acrylate (10 mL, 113 mmol) was then added, and the mixture was 
stirred at room temperature for 3 hours. After that 1 mL of methanol and an aqueous 
solution saturated with NaHCO3 were then added to the reaction. The organic layer 
was separated, and the aqueous phase was extracted 2 times with ethyl acetate. The 
organic phase was dried over Na2SO4 and Na2CO3 and evaporated to dryness. The 
product was purified column chromatography (Pet/EtOAc 9:1) to give compound 3 as 
a yellow oil (22.0 g, 95 %). 
1H NMR (300 MHz, CDCl3, 298 K) δ 7.30 – 7.23 (m, 10H), 3.75 – 3.48 (m, 9H), 2.94 
(d, J = 14.2 Hz, 2H), 2.68 – 2.54 (m, 4H), 1.97 – 1.91 (m, 2H), 1.76 – 1.70 (m, 2H) 
ppm. 
13C NMR (75 MHz, CDCl3, 298 K) δ 138.6 (C), 128.6 (CH), 127.9 (CH), 126.8 (CH), 
93.3 (C), 63.3 (CH2), 60.9 (CH2), 58.1 (CH2), 51.0 (CH3), 30.8 (CH2), 27.1 (CH2). 
MS (ESI+): m/z = 412.52 (100%, [M+H]+). Calc. for C23H29N3O4: 411.22. 
 
7,10-Dibenzyl-1,7,10-triazaspiro[4.6]undecan-2-one (4) 
Procedure 4A. A 50 % Raney-Nickel slurry (26 g) was washed with methanol and 
centrifuged 3 times to completely remove water. This Raney-Nickel slurry in methanol 
was added to a solution of compound 3 (13.0 g, 31.6 mmol) and methanol (120 mL 
total). The mixture was stirred at RT under hydrogen atmosphere (10 bar) for 192 h 
then filtered through Celite and dried under vacuum. The residue was taken up in 
toluene, refluxed for 20 h and then evaporated to dryness. The product is purified by 
crystallization from ethyl acetate, vacuum filtration and washing with Et2O to give 
compound 4 as white needles (5.76 g, 52 %). 
Procedure 4B. A mixture of compound 3 (1.00 g, 2.43 mmol), iron (0.679 g, 12.2 
mmol) and acetic acid (5 mL) was refluxed for 20 h. Then the mixture was quenched 
in water, basified with NaHCO3 and treated with 5 g of EDTA disodium. The resulting 





phase was dried (Na2SO4, Na2CO3) and removed under vacuum. The product is 
purified by crystallization from ethyl acetate, vacuum filtration and washing with Et2O 
to give compound 4 as white needles (0.419 g, 49 %). 
Procedure 4C. A mixture of compound 3 (11.7 g, 28.5 mmol), zinc (9.31 g, 142 mmol) 
and acetic acid (70 mL) is refluxed for 20 h. Then the mixture was quenched in water, 
basified with NaHCO3 and treated with 14 g of EDTA disodium. The resulting 
suspension was filtered and extracted three times with ethyl acetate. The organic 
phase was dried (Na2SO4, Na2CO3) and removed under vacuum. The product is 
purified by crystallization from ethyl acetate, vacuum filtration and washing with Et2O 
to give compound 4 as white needles (1.53 g, 15 %). 
1H NMR (300 MHz, CDCl3, 298 K) δ 7.32 – 7.26 (m, 10H), 3.71 – 3.45 (m, 4H), 2.84 
– 2.57 (m, 6H), 2.21 (s, 1H), 2.04 (t, J = 7.9 Hz, 2H), 1.57 (t, J = 7.8 Hz, 2H) ppm. 
13C NMR (75 MHz, CDCl3, 298 K) δ 176.5 (C), 129.0 (C), 128.5 (CH), 127.4 (CH), 
65.3 (CH2), 64.0 (CH2), 62.3 (C), 58.5 (CH2), 29.9 (CH2), 29.2 (CH2) ppm. 
MS (ESI+): m/z = 350.37 (100%, [M+H]+). Calc. for C22H27N3O: 349.22. 
 
7,10-dibenzyl-1,7,10-triazaspiro[4.6]undecane (5) 
Compound 4 (4.10 g, 11.7 mmol) was dissolved in dry THF (20 mL) and LiAlH4 (1.34 
g, 35.2 mmol) was added portionwise under nitrogen atmosphere. The reaction was 
stirred and refluxed under nitrogen atmosphere for 24 h. The mixture was quenched 
with NaOH 50% aqueous solution and then with water and the organic phase was 
separated. The aqueous layer was extracted three times with DCM, the organic 
phases were collected and dried under vacuum.  The product was purified by column 
chromatography (EtOAc/MeOH 95:5 – 8:2) to yield compound 5 as a yellow oil (3.80 
g, 97 %). 
1H NMR (300 MHz, CDCl3, 298 K) δ 1H NMR (300 MHz, CDCl3, 298K) δ 7.33 – 7.19 
(m, 10H), 6.19 (s, 1H), 3.64 (d, J = 13.1 Hz, 2H), 3.58 (d, J = 13.1 Hz, 2H), 2.81 – 2.50 
(m, 8H), 1.95 – 1.91 (m, 4H), 1.51 – 1.47 (m, 2H) ppm. 
13C NMR (75 MHz, CDCl3, 298 K) δ 139.9 (C), 129.2 (CH), 128.3 (CH), 127.1 (CH), 
65.0 (CH2), 64.8 (C), 63.7 (CH2), 57.6 (CH2), 44.5 (CH2), 35.4 (CH2), 24.0 (CH2) ppm. 







Compound 5 (3.60 g, 10,7 mmol) was dissolved in methanol, Pd/C (5 %, 3.60 g) was 
added, and the mixture was stirred under hydrogen atmosphere (10 atm) at room 
temperature for 28 h. The reaction was filtered through Celite and evaporated to give 
compound 6 as a brown oil (1.67 g, quant.). 
1H NMR (300 MHz, D2O, 298 K) δ 3.56 (t, J = 7.0 Hz, 2H), 3.47 – 3.34 (m, 6H), 2.32 
– 2.11 (m, 6H) ppm. 
13C NMR (75 MHz, D2O, 298 K) δ 58.2 (C), 54.7 (CH2), 48.7 (CH2), 45.5 (CH2), 33.9 
(CH2), 23.2 (CH2). 
MS (ESI+): m/z = 156.15 (100%, [M+H]+). Calc. for C8H17N3: 155.14. 
 
tri-tert-Butyl 2,2',2''-(1,7,10-triazaspiro[4.6]undecane-1,7,10-triyl)triacetate (7) 
Procedure 7A. Compound 6 (0.542 g, 3.49 mmol) was dissolved in acetonitrile (10 
mL) and potassium carbonate (1.93 g, 14.0 mmol) was added. tert-Butyl 
bromoacetate (1.7 mL, 11.5 mmol) was added dropwise over 1 h at 0°C and then the 
reaction was stirred at room temperature for 18 h. The mixture was filtered, 
evaporated and purified by column chromatography (Pet/EtOAc 9:1 – 85:15) to give 
compound 7 as a yellow oil (0.531 g, 31 %). 
Procedure 7B. Compound 6 (0.513 g, 3.30 mmol) was dissolved in N,N-
dimethylacetamide (2 mL) and the potassium carbonate (2.74 g, 0.0198 mmol) was 
added. The tert-butyl bromoacetate (2.9 mL, 0.0198 mmol) was added dropwise over 
1 h at 0°C and then the reaction was stirred at room temperature for 18 h. Then water 
was added to the mixture which was extracted three times with ether, dried (Na2SO4, 
Na2CO3), evaporated under vacuum and purified by column chromatography 
(Pet/EtOAc 9:1 – 85:15) to give compound 7 as a yellow oil (0.477 g, 29 %). 
Procedure 7C. Compound 6 (0.500 g, 3.22 mmol) was dissolved in acetonitrile (10 
mL) and potassium carbonate (1.93 g, 14.0 mmol) and sodium sulfate (1.83 g, 13.0 
mmol) were added. tert-Butyl bromoacetate (1.7 mL, 11.5 mmol) was added dropwise 
over 3 h at 0 °C and then the reaction was stirred at room temperature for 18 h. The 
mixture was filtered, evaporated and purified by column chromatography (Pet/EtOAc 





1H NMR (300 MHz, CDCl3, 298 K) δ 3.37 (s, 2H), 3.04 (br s, 4H), 2.69 – 2.44 (m, 10H), 
1.49 (br s, 2H), 1.35 – 1.24 (m, 29H) ppm. 
13C NMR (75 MHz, CDCl3, 298 K) δ 171.5 (C), 170.3 (C), 80.4 (C), 79.8 (C), 65.3 (C), 
63.4 (CH2), 61.9 (CH2), 58.8 (CH2), 51.9 (CH2), 51.0 (CH2), 35.9 (CH2), 27.9 (CH3), 
27.8 (CH3), 21.7 (CH2). 
MS (ESI+): m/z = 498.35 (100%, [M+H]+). Calc. for C26H47N3O6: 497.35. 
 
2,2',2''-(1,7,10-Triazaspiro[4.6]undecane-1,7,10-triyl)triacetic acid (8) 
Compound 7 (0.262 g, 0.526 mmol) was dissolved in trifluoroacetic acid (2 mL) and 
left at room temperature for 28 h. The mixture was dried under vacuum and the 
residue was dissolved in methanol, precipitated with ether, centrifugated and the 
supernatant was poured away. This procedure was repeated three times. The product 
was purified by chromatography on XAD (eluent: H2O) to give compound 8 as an off-
white solid (0.126 g, 73 %).  
1H NMR (300 MHz, D2O, 298 K) δ 4.32 (s, 2H), 3.94 (br s, 4H), 3.83 – 3.64 (m, 6H), 
3.53 – 3.36 (m, 6H), 2.24 (s, 2H) ppm. 
13C NMR (75 MHz, D2O, 298 K) δ 172.7 (C), 170.7 (C), 74.7 (C), 59.1 (CH2), 59.0 
(CH2), 58.6 (CH2), 54.3 (CH2), 54.1 (CH2), 33.9 (CH2), 21.2 (CH2) ppm. 
MS (ESI+): m/z = 330.17 (100%, [M+H]+). Calc. for C14H23N3O6: 329.16. 
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Chapter 6: Cb-tebpm, 













Cyclam (1,4,8,11-tetraazacyclotetradecane) is a macrocyclic polyamine and an 
important starting material for the preparation of metal complexes exploited as CAs 
such as TETA.1 (Figure 6.1) 
Cyclam based chelating agent are usually believed to chelate metals forming 
complexes with lower thermodynamic stability and kinetic inertness if compared to the 
cyclen derived counterparts.2,3 However, recently many authors reported that cross-
bridged cyclam derivatives (Figure 6.1), bearing a 1,8-ethylene unit, form metal 
complexes with great kinetic inertness.4–8  
 
 
Figure 6.1. TETA and cross-bridged cyclam derivatives. 
 
In particular, Rodríguez-Rodríguez et al. have reported in 2014 that a cross-bridged 
cyclam bearing two picolinate pendant arms (cb-tedpa) present high kinetic inertness. 
In fact, Ln-cb-tedpa complexes are stable even in very harsh conditions such as 2 M 
HCl for five months, while Ln-DOTA complexes dissociate 6.9 h under the same 
conditions. Even in competitions experiments, with high concentrations of 
endogenous metal ions and anions, Ln-cb-tedpa complexes are stable for many days. 
Moreover, Ln-cb-tedpa are present as a single coordination isomer both in solution 
and solid state due to the rigid structure of the ligand. Rodríguez-Rodríguez et al. 
report also that Ln-cb-tedpa have a q value equal to 0.25 – 0.35, which means that 
there is not a water molecule directly bound to the metal, but the second hydration 





Intrigued by this information we decided to prepare an analogue of cb-tedpa with two 




Figure 6.2. cb-tedpa and cb-tebpm. 
 
Ln-complexes of such ligand should retain the rigid structure and the kinetic inertness 
guaranteed by the cross-bridged cyclam and complexation properties since the very 
similar structure to cb-tedpa. But the two hydroxy groups should confer cb-tebpm 
additional properties, such as an extended network of hydrogen bonds and a shorter 
and slightly weaker Ln-O bond. These three new features can, respectively, raise the 
q value, increase the relaxivity and allow a partial bond to bulk water molecules.8,9 
The dichotomy between the carboxylic group and the hydroxy group as pendant arms 
in ligands and metal complexes thereof is also exploited in the clinically approved MRI 
CA gadoteridol. The latter in fact differ from DOTA just for this simple substitution (an 
OH instead of a COOH) but for this reason gadoteridol gains the additional features 
mentioned above, reaching higher transversal and longitudinal relaxivity if compared 
to Gd-DOTA. High relaxivity and high kinetic and thermodynamic stability are very 
interesting features for an MRI CA since they allow to reduce dose and the toxicity 
related to free gadolinium ions.9 
 
Results and discussion 
Compound 2B was prepared by refluxing 1 in aqueous 48 % HBr solution for 1 h. 





compound 2B in 40 % yield, by-product 2A in 15 % and recovering of almost all 
unreacted starting material 1. Compound 3 was then alkylated with compound 2B in 
acetonitrile using potassium carbonate as base. Addition of 2B lasted 2.5h at 0°C and 
the reaction finished in 20 h at room temperature. The product (cb-tebpm) is purified 
by chromatography on silica gel and obtained in 89 % yield. [Gd(cb-tebpm)] was 
prepared by reacting cb-tebpm with gadolinium triflate, in a n-butanol/DIPEA mixture, 
under microwave irradiation (300 W) at 150 °C and 250 psi for 18 h. Column 
chromatography on silica gel afforded final compound ([Gd(cb-tebpm)]) as a white 
solid in 31 % yield. (Figure 6.3) 
 
 
Figure 6.3. Synthesis of cb-tebpm and [Gd(cb-tebpm)]. 
 
From preliminary complexometric data we have learned that the gadolinium complex 
[Gd(cb-tebpm)] shows a kinetic inertness comparable or even higher than [Gd(cb-
tedpa)], even in strongly dissociating conditions (i.e. strong acidic media). However, 
other complexometric and relaxometric experiments must be undertaken to 






The synthetic procedure to prepare cb-tebpm presents the great advantage of 
avoiding use of protecting groups, which is indispensable in the preparation of cb-
tedpa and, unfortunately, most other chelating agents with a complex structure.3,8,9 
This aspect shortens the synthesis of cb-tebpm and could help in a possible future 
production on a larger scale.  
Future development will concern the optimization of the complexation step and the 
substitution of chromatography techniques with other purification procedure, i.e. 
precipitations or crystallizations. Moreover, we will study the complexation properties 
(such as kinetic and thermodynamic stability) of cb-tebpm with other biomedically 




Materials and methods 
Solvents and starting materials were purchased from Merck or TCI and used without 
further purification. All aqueous solutions were prepared from ultrapure laboratory 
grade water (18 MΩ・cm) obtained from Millipore/MilliQ purification system. 1H and 
13C NMR spectra were recorded at 300 MHz on a Jeol Eclipse ECP300 spectrometer. 
Chemical shifts are reported in ppm with the protic impurities of the deuterated solvent 
as the internal reference. Mass spectra were obtained with a Thermo Finningan LCQ-
Deca XP-PLUS ion trap spectrometer equipped with an electrospray source. TLC 
were performed with silica gel (MN Kieselgel 60F254) and visualized by UV or sprayed 
with Dragendorff reagent or alkaline KMnO4. Column chromatography was carried out 








2,6-Bis(bromomethyl)pyridine (2A) and 2-(bromomethyl)-6-(hydroxymethyl)-
pyridine (2B) 
Compounds 2A and 2B were synthesized by refluxing a mixture of 2,6-
pyridinedimethanol (1) (3.04 g, 21.8 mmol) and 48 % aqueous HBr (25 mL) for 1 h. 
The mixture was cooled to 0°C and basified by slow addition of Na2CO3 and water. 
The mixture was then extracted with methylene chloride in three portions and dried 
(Na2SO4, Na2CO3). The residue was purified by chromatography on silica gel 
(Pet/EtOAc 5:5) to yield 2A (0.851 g, 15 %) and 2B (1.78g, 40 %) both as white 
crystals. 
 
2,6-Bis(bromomethyl)pyridine (2A)  
1H NMR (300 MHz, CDCl3, 298 K) δ 7.69 (t, J = 7.7 Hz, 1H), 7.36 (d, J = 7.7 Hz, 2H), 
4.52 (s, 4H) ppm. 




1H NMR (300 MHz, Acetone-d6, 298 K) δ 7.81 (t, J = 7.7 Hz, 1H), 7.45 (d, J = 7.2 Hz, 
1H), 7.41 (d, J = 7.3 Hz, 1H), 4.68 (s, 2H), 4.62 (s, 2H) ppm. 
13C NMR (75 MHz, Acetone-d6, 298 K) δ 162.5 (C), 156.8 (C), 138.5 (CH), 122.5 




A solution of compound 2B (0.900 g, 4.46 mmol) in acetonitrile (5 mL) was added at 
0 °C in 2.5 h to a suspension of 1,4,8,11-tetraazabicyclo[6.6.2]hexadecane (3) (0.504 
g, 2.23 mmol), CH3CN (5 mL) and K2CO3 (1.54 g, 11.1 mmol) and then the mixture 
was stirred at RT for 20 h. The mixture was dried under vacuum and the residue was 
purified by chromatography on silica gel (DCM/MeOH 8:2) to afford compound 4 





1H NMR (300 MHz, CD3OD, 298 K) δ 7.79 (t, J = 7.7 Hz, 2H), 7.43 (d, J = 7.8 Hz, 2H), 
7.28 (d, J = 7.4 Hz, 2H), 4.69 (s, 4H), 3.86 (s, 4H), 3.16 – 2.64 (m, 20H), 1.78 – 1.71 
(m, 4H) ppm. 
13C NMR (75 MHz, CD3OD, 298 K) δ 164.8 (C), 157.9 (C), 138.8 (CH), 124.0 (CH), 
120.7 (CH), 65.8 (CH2), 59.6 (CH2), 58.3 (CH2), 55.9 (CH2), 54.2 (CH2), 53.0 (CH2), 
52.6 (CH2), 25.3 (CH2) ppm. 
MS (ESI+): m/z = 469.44 (100%, [M+H]+), 235.44 (41%, [M+2H]2+). Calc. for 




Gadolinium triflate (0.553 g, 0.915 mmol) and DIPEA (0.23 mL, 1.34 mmol) were 
added to a mixture of cb-tebpm (0.210, 0.448 mmol) and n-BuOH (2 mL) and the 
resulting solution was stirred under microwave radiation (300 W) at 150 °C and 250 
psi for 18 h. The solvent was dried under vacuum and the product was purified by 
chromatography on silica gel (CH3CN/NH3 9:1 - 85:15 – 8:2) to yield [Gd(cb-tebpm)] 
(0.148 g, 31 %) as an off-white solid.  
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Contrast Enhanced Magnetic Resonance Imaging (MRI) with gadolinium (GdIII)-based 
contrast agents (GBCAs) is fundamental for accurate diagnosis of numerous diseases 
and disorders. Approximately 30–40% of all MRI scans, corresponding to roughly 30 
million administrations per year worldwide,1 are performed with the intravenous (IV) 
administration of GBCAs. The available GBCAs are classified based on their 
molecular structure as either linear or macrocyclic. A major feature that distinguishes 
these two subclasses is kinetic inertness, which is higher for the macrocyclic GBCAs 
due to the closed, cage-like structure of the molecules (Scheme 7.1).2–8  
 
 
Scheme 7.1. Structures of macrocyclic ligands. Formulas and trade names of GdL 
complexes used as MR contrast agents (NMG: N-methylglucamine). 
 
The observation in 20149 of an increase in signal intensity on non-contrasted T1-





Pallidus) of patients that had undergone numerous exposures to certain linear GBCAs 
led to major concern worldwide about the long term safety of these GBCAs. 
Subsequent studies, that revealed a correlation between the degree of hyperintensity 
seen and the cumulative dose of linear GBCA administered, led to certain regulatory 
authorities (for example, the European Medicines Agency) suspending all general-
purpose linear GBCAs for clinical use,10 despite the fact that no harmful effects or 
clinical consequences arising from T1-hyperintensity have been observed yet. The 
concern centres on the belief that dissociation of the least kinetically inert linear 
GBCAs leads to release of Gd3+ which is then retained in brain and body tissues, 
potentially leading to long term harmful consequences to the patient. A consequence 
of this concern has led to the increased use of macrocyclic GBCAs, whose 
dissociation half-lives under physiological conditions far exceed 1000 years.2,8 
Unfortunately, moving from linear to macrocyclic GBCAs, a limited number of persons 
have shown Gd retention also with macrocyclic GBCAs and fewer still have 
considered the notable differences amongst the macrocyclic GBCAs in terms of Gd 
retention. Recent studies have shown that Gd retention occurs also with macrocyclic 
GBCAs, even after relatively few administrations.11,12 Murata et al. found markedly 
higher levels of Gd retention after gadobutrol administration than after gadoteridol 
administration, indicating that some dissociation-independent retention mechanisms 
play a role. Stanescu et al., in a very recent study on pediatric decedents, found Gd 
traces after single or multiple administrations of both gadoteridol and gadoterate 
meglumine, with higher values for the latter. Analogously, other clinical and non-
clinical studies have shown that these GBCAs can be retained for extended periods 
as intact GdIII complex in living systems.13–15 In support of these findings in humans, 
several non-clinical studies have noted marked differences amongst the macrocyclic 
GBCAs in terms of Gd retention, with the least retention, and most rapid elimination, 
consistently reported for gadoteridol.16–20 After injection, all GBCAs distribute rapidly 
in the vascular system and the interstitial fluid resulting in non-specific biodistribution 
in the different tissues.21 Although none of the macrocyclic GBCAs binds to plasma 
proteins, their interaction with components of the interstitial space has not been 
thoroughly investigated yet. The interstitial fluid consists of several low and high 





phosphate ions in the interstitial fluid and plasma are similar. However, the 
concentrations of the high molecular weight components (e.g. total protein, albumin) 
in the interstitial fluid are significantly lower than those in plasma. Moreover, the 
interstitial space cannot be regarded as a homogenous solution due to the presence 
of proteins and polysaccharides in solid and semi-solid phase. Interactions between 
the intact GdIII-complexes and the solid/semi-solid components of the interstitial space 
may explain their long-term retention in living systems. Collagen is one of the most 
abundant components of the interstitial space. Approximately, 25% of the total protein 
mass is collagen of which 80% (ca. 2.65 kg in a 70 kg patient) is Type I collagen.23–25 
In the past, collagen has been considered a target for MR molecular imaging agents26 
to reveal the presence of fibrotic scars, which are typical of conditions such as 
myocardial infarct,27 and liver fibrosis.28 However, the agent developed was based on 
a cyclic decapeptide, purportedly selected by phage display technology to bind Type 
I collagen. The same peptide was also utilised to develop a PET imaging agent, after 
chelation of 68Ga.29,30 Using a different approach, another collagen-specific 
peptidomimetic was identified and labelled with 99mTc for SPECT imaging,31 while a 
less specific lipophilic effect contributed to the binding of hexadecyl-4-[18F] 
fluorobenzoate (18F-HFB) to collagen matrices.32 To the best of our knowledge, no 
other indications of collagen binding have been reported for commercial or research-
type contrast agents. Therefore, it was important to determine the affinity of the three 
approved GBCAs gadoterate meglumine, gadobutrol, gadoteridol as well as Gd(HB-
DO3A) to solid Type I collagen (bovine Achilles tendon) by both ultrafiltration and 
dialysis, with the use of cellulose membranes. Gd(HB-DO3A) is not commercially 
available, but it was synthesised for the study to assess the relevance, if any, of a 
side-chain terminal ethyl group relative to the side-chain terminal methyl group of 
gadoteridol. The kinetics of adsorption and desorption processes to/from collagen 
were also characterised. The effects of the dialysis membrane on GBCA adsorption 








Results and discussion  
 
Synthesis of HB-DO3A ligand  
HB-DO3A was prepared according to the synthesis reported in Scheme 7.2. 
Alkylation of DO3A(tBu)333 in refluxing 1,2-epoxybutane led to the formation of the 2-
hydroxy-1-butyl derivative HB-DO3A(tBu)3, along with a small amount of the 1-
hydroxy-2-butyl regioisomer. The latter was removed by column chromatography, 
allowing to isolate analytically pure HB-DO3A(tBu)3 in 91% yield. The chelating agent 
HB-DO3A was obtained in 82% yield by removal of the t-butyl groups with 
TFA/anisole, followed by crystallisation from 2-propanol. The GdIII-complex was 
prepared by reacting HB-DO3A with an equivalent amount of GdCl3·6H2O in aqueous 
solution, kept neutral by constant addition of NaOH.  
 
 








Affinity of macrocyclic GBCAs to collagen 
Affinity to collagen was studied by ultrafiltration of a collagen suspension after 4 h 
equilibration at pH = 7.4 and 37 °C in the presence of 0.5–7.0 mM GBCA. The amount 
of GBCAs adsorbed by collagen show saturation curves as a function of GBCA 
concentration (Figure 1). 
 
 
Figure 7.1. Amount of gadoterate meglumine (◆), gadobutrol (⚫), gadoteridol (◼) and 
Gd(HB-DO3A) () adsorbed by collagen at pH = 7.4 and 37 C in 1.0 mM Na2HPO4 
and 0.15 M NaCl solution. [GdL] values were obtained as the average of three parallel 
experiments. [GdL] values are characterized by standard deviation <3%. 
 
These saturation curves showing the extent of the reversible monolayer adsorption of 
the GBCAs on the surface of solid materials and can be described by the Langmuir 
isoterm:34 
                                                                                                                                                                                         
(7.1) 
where q, Q, b and [GdL] are the amounts of adsorbed GBCA, the respective maximum 
amount, the affinity constant and the equilibrium concentration of GBCA in the buffer 
solution, respectively. The affinity constant (b) and maximum amount of adsorbed 
GBCA (Q) were obtained by fitting the data in Figure 7.1 to Equation 7.1 and are 














gadobutrol gadoteridol Gd(HB-DO3A) 
logb 2.54  0.05 2.52  0.04 2.55  0.05 2.410.06 
Q 106 7.1  0.8 6.7  0.9 5.1  0.8 4.4  0.5 
logPa -2.87 b -2.2 b/-2.0c -1.91d/-1.98b -1.71d 
Table 7.1. The affinity constant (b) and maximum amount (Q, mol GdIII/g dry collagen) 
of adsorbed GBCAs on collagen obtained by ultrafiltration (pH = 7.4 and 37 C in 1.0 
mM Na2HPO4 and 0.15 M NaCl solution). a logP values were determined in 
butanol:water, b Ref. 35, c Ref. 36, d In this work: [GdL]tot = 10 mM, [HEPES] = 25 mM, 
pH = 7.4. 
 
To compare lipophilicity, log P values of the GBCAs (partition coefficients in 
butanol:water), are indicated in Table 7.1. While the affinity of the different GBCAs to 
collagen is comparable, the maximum loading capacity of collagen with gadoteridol 
and Gd(HB-DO3A) is somewhat lower (ca. 26% and 36%, respectively) than with 
gadoterate meglumine and gadobutrol, possibly reflecting their different physico-
chemical properties at physiological pH Gadoterate has a net negative charge, while 
the hydroxyl groups of gadobutrol, gadoteridol and Gd(HB-DO3A) are characterized 
by different protonation constants. In pH-potentiometric titrations of 0.002 M solutions 
of Gd(BT-DO3A), Gd(HP-DO3A) and Gd(HB-DO3A) complexes with 0.2 M NaOH 
solution, base consumption was observed at pH slightly above 7.0, due to the 
dissociation of H+ ion from the alcoholic –OH groups of the pendant arm (Equation 
7.2).  
 
GdLH-1 + H+  GdL                                                                                                    (7.2)                                                 
  
The protonation constants of gadobutrol, gadoteridol and Gd HB-DO3A) obtained by 

















T (C) Gd(BT-DO3A) Gd(HP-DO3A) Gd(HB-DO3A) 
25 8.99  0.04, 9.48a 11.36a, 11.31b 10.92  0.01 
37 8.73  0.03 11.39  0.04 10.88  0.02 
Table 7.2. Protonation constants (logKHGdLH-1) Gd(BT-DO3A), Gd(HP-DO3A) and 
Gd(HB-DO3A) complexes (0.15 M NaCl). a Ref. 8 (0.1 M NaCl, 25C); b Ref. 37 (0.15 
M NaCl, 25C). 
 
The log KGdLH−1 values (Table 7.2) that characterize the protonation of the coordinated 
–O− groups of gadobutrol, gadoteridol and Gd(HB-DO3A) are slightly influenced by 
temperature. Moreover, whereas the protonation constants of gadoteridol and Gd(HB-
DO3A) are very similar, the log KGdLH−1 value of gadobutrol is significantly lower, which 
might be explained by the electron withdrawing and electrostatic repulsion effects of 
the neighbouring non-coordinated –OH groups in the butrol pendant. Additionally, the 
alkoxide –O− group might form the local H bond with the neighbouring –OH groups 
which can stabilize the conjugate base of gadobutrol. Based on these values, their 
species distribution was calculated under physiological conditions (Figures 7.6 – 7.8). 
While gadoteridol and [Gd(HB-DO3A)] are fully neutral, the species distribution of 
gadobutrol shows the presence of ∼5.7% of an anionic form ([GdLH−1]−) with a 
negative charge under physiological conditions. Type I collagen has positive charges 
under physiological conditions due to lysine and hydroxyproline rich domains (pI = 
9.3).38,39 Consequently, electrostatic interactions between collagen and both 
gadoterate and partially ionized gadobutrol might explain their higher Q values 
compared to gadoteridol and Gd(HB-DO3A) at physiological pH. The presence of the 
methyl and ethyl groups in the gadoteridol and Gd (HB-DO3A) sidechains may be 
responsible for their lower Q values, with the more hydrophobic ethyl group less in 






Rates of the adsorption and desorption 
processes  
It is known that retention of GBCAs in living systems is strongly influenced by their 
pharmacokinetic properties. The faster they are eliminated from blood, the lower the 
opportunity to distribute into other deeper compartments. However, also their rates of 
adsorption and desorption on collagen, as a major representative of interstitial tissue 
components, might play a role. These kinetic parameters have been determined by 
dynamic dialysis. The amounts of GBCAs adsorbed onto collagen as a function of 
time were used to calculate the rate of adsorption and desorption (Figure 7.2 and 
Figure 7.3).  
 
 
Figure 7.2. Amount of gadoterate meglumine (◆), gadobutrol (⚫), gadoteridol (◼) and 
Gd(HB-DO3A) () adsorbed by collagen (150 mg dry collagen) as a function of time 







Figure 7.3. Amount of gadoterate meglumine (◆), gadobutrol (⚫), gadoteridol (◼) and 
Gd(HB-DO3A) () desorbed from collagen (150 mg dry collagen) as a function of 
time ([GBCA] = 1.0 mM, pH = 7.4, 37 C, 1.0 mM Na2HPO4, 0.15 M NaCl). 
 
The rate constants characterizing the adsorption (kad) and desorption (kde) of GBCAs 
on collagen were calculated by fitting the kinetic data in Figure 7.2 and Figure 7.3 to 
Equation 7.6. By considering the volume of collagen suspension in the membrane, 
we calculated also the rate constants (kin and kout) characterizing the in- and out- 
diffusion of the GBCAs through the dialysis membrane in the absence of collagen, 















0.013  0.003 0.012  0.003 0.009  0.002 
















Table 7.3. The rate constants characterizing the adsorption (kad) and desorption (kde) 
of GBCAs on collagen and the diffusion of the GBCAs (kin and kout) through the dialysis 





The rate constants characterizing the adsorption and desorption of gadoterate 
meglumine, gadobutrol and gadoteridol on collagen (kad, kde) are very similar and 
essentially identical to those for free diffusion through the dialysis membrane (kin, kout) 
in the absence of collagen. Based on these data, it can be assumed that the diffusion 
of the GBCAs through the dialysis membrane is the rate determining step before the 
fast adsorption, or after the fast desorption, of GBCAs to/from collagen. The kad and 
kde rate constants of Gd(HB-DO3A) are somewhat lower than those of other GBCAs, 
which might be explained by the hydrophobic character of the 2-hydroxybutyl 
sidechain which results in slightly slower in- and out-diffusion processes of Gd(HB-
DO3A) through the membrane.  
 
The extent of the in vivo retention of macrocyclic 
GBCAs on collagen  
The extent of the retention of GBCAs can be estimated based on the interaction 
between GBCAs and collagen (Table 7.1) and the known pharmacokinetic data of 
GBCAs, reported previously.21,40 After IV administration, the GBCAs distribute very 
rapidly in the vascular system and diffuse into the interstitial space of the body, which 
occurs simultaneously with the elimination of the GBCAs from the blood via kidneys. 
By considering the collagen adsorbent as a third compartment in the interstitium, the 
concentration of GBCAs in blood, interstitial space and collagen can be described by 
an open three compartment model (Figure 7.4). The rate constant characterizing the 
distribution (kint = k–int = ln 2/t1/2 α) was set equal to 9.6 × 10−4 s−1, the value measured 
for gadopentetate dimeglumine (Gd(DTPA)2−) previously40 since corresponding data 







Figure 7.4. The distribution, adsorption/desorption and the elimination of GBCAs in 
open three-compartment model. 
 
The elimination rate (kel = ln 2/t1/2 β) was set equal to 1.2 × 10−4 s−1 for gadoterate 
meglumine, gadoteridol and Gd(HB-DO3A) and equal to 1.28 × 10−4 s−1 for 
gadobutrol.21 Based on the model presented in Figure 7.4, the interaction with 
collagen can be described as a homogenous linear system of first-order differential 
equations, each subjected to an initial condition as described elsewhere.3 The 
concentrations of the GBCAs during their distribution in the collagen, vascular and 
interstitial spaces and the elimination from the vascular space were calculated and 
the data obtained are shown in Figure 7.12. The GBCA amount adsorbed by collagen 







Figure 7.5. Simulation of the amounts of gadoterate meglumine (1), gadobutrol (2), 
gadoteridol (3) and Gd(HB-DO3A) (4) adsorbed by collagen. The distribution volume 
was 0.25 L per kg body weight, the weight of total collagen was 2.65 kg, the volume 
of the plasma was taken 3.5 L and the dose of CA was 0.1 mmol per kg body weight 
for a 70 kg patient. 
 
These data are in agreement with clinical evidence that approximately 98% of the 
GBCA is eliminated from the body of patients with normal kidney function in about 48 
h.21 After the same length of time, the amount of the GBCAs adsorbed by collagen 
was found to be 0.6, 0.5, 0.4 and 0.3% of the dose for gadoterate meglumine, 
gadobutrol, gadoteridol and Gd (HB-DO3A), respectively. These findings suggest that 
the maximum loading capacity (Q values) influences the amount of GBCAs that can 
be adsorbed by collagen in vivo. It is conceivable that the whole or fractional charge 
has a relevant role for the adsorption of gadoterate meglumine and gadobutrol, the 
latter being further assisted by the possibility of establishing hydrogen bonds with 
collagen fibrils, through the free pair of hydroxy groups, as already hypothesized to 
explain the higher retention of gadobutrol in rats.19,20 Conversely, for gadoteridol and 
Gd(HB-DO3A) the presence of the hydrophobic methyl and ethyl groups, respectively, 
may act synergistically with their neutrality to decrease adsorption, preventing both 







General information  
Solvents and starting materials were purchased from SigmaAldrich or TCI Europe and 
used without further purification. All aqueous solutions were prepared from ultrapure 
laboratory grade water (18 MΩ・cm) obtained from Millipore/MilliQ purification 
system. 1H and 13C NMR spectra were recorded at 300 MHz on a Jeol Eclipse 
ECP300 spectrometer. Chemical shifts are reported in ppm with the protic impurities 
of the deuterated solvent as the internal reference. Mass spectra were obtained with 
a Thermo Finningan LCQ-Deca XP-PLUS ion trap spectrometer equipped with an 
electrospray source. TLC were performed with silica gel (MN Kieselgel 60F254) and 
visualized by UV or sprayed with Dragendorff reagent or alkaline KMnO4. 
 
Synthesis of HB-DO3A and Gd(HB-DO3A) 
1,4,7-Tris(t-butoxycarbonylmethyl)-10-(2-hydroxybutyl)-1,4,7,10-tetraazacyclo-
dodecane (HB-DO3A-tBu): DO3A(tBu)3 (1.73 g, 3.36 mmol)33 was suspended in 5 mL 
of 1,2-epoxybutane and refluxed for 5 h. The clear solution was evaporated under 
vacuum and the residue purified by column chromatography (EtOAc/MeOH 8:2 – 7:3) 
to remove a small amount of the 1-hydroxy-2-butyl regioisomer, giving compound HB-
DO3A(tBu)3 as a light brown oil (1.80 g, 91 %).  
1H NMR (300 MHz, CDCl3, 298 K) δ 3.75 – 2.65 (m, 26H), 1.44 – 1.33 (m, 29H), 0.87 
(t, J = 7.2 Hz, 3H) ppm. 
13C NMR (75 MHz, CDCl3, 298 K) δ 170.5 (3 C), 81.2 (3 C), 67.6 (CH), 65.7 (CH2), 
59.7 (CH2), 56.6 (CH2), 56.4 (CH2), 53.4 (CH2), 52.9 (CH2), 51.4 (CH2), 50.2 (CH2), 
28.2 (3CH3), 9.8 (CH3) ppm.  
MS (ESI+): m/z = 587.4 (100%, [M+H]+). Calc. for C30H58N4O7: 586.8. 
 
1,4,7-Tris(carboxymethyl)-10-(2-hydroxybutyl)-1,4,7,10-tetraazacyclododecane (HB-
DO3A): HB-DO3A(tBu)3 (1.80 g, 3.07 mmol), 2 mL of anisole and 10 mL of TFA were 
mixed and stirred at RT for 63 h. The mixture was evaporated under vacuum and the 





supernatant removed by decantation. This procedure was repeated three times. The 
product was crystallised from isopropyl alcohol to give compound HB-DO3A as a 
white crystalline solid (1.05 g, 82%).  
1H NMR (300 MHz, D2O, 298 K) δ 3.95 – 2.95 (m, 25H), 1.47 (m, 2H), 0.88 (t, J = 7.3 
Hz, 3H) ppm.  
13C NMR (75 MHz, D2O) δ 174.3 (2C), 170.2 (C), 67.5 (CH), 59.3 (CH2), 56.8 (CH2), 
53.9 (2 CH2), 51.7 (8 CH2), 28.2 (CH2), 9.1 (CH3) ppm. MS (ESI+): m/z = 419.3 (100%, 
[M+H]+). Calc. for C18H34N4O7: 418.5. 
 
Gd(HB-DO3A): Gd(HB-DO3A) was prepared by dissolving GdCl3∙6 H2O (1.85 g, 5.0 
mmol) in 10 mL aqueous solution of H3HB-DO3A (2.10 g 5.0 mmol). The solution was 
stirred at room temperature for 16 h. The pH of the solution was kept constant by 
addition of solid NaOH (pH = 7.0). The formation of GdIII-complexes was confirmed 
by mass spectrometry.  
MS (ESI+): m/z = 596.2 (100%, [M+Na]+). Calc. for C18H35N4O7Gd: 575.7. 
 
Acid-base properties of Gd(BT-DO3A), Gd(HP-
DO3A) and Gd(HB-DO3A) complexes 
Materials: The chemicals used for the experiments were of the highest analytical 
grade. The concentration of the aqueous solution HB-DO3A ligand was determined 
by pH-potentiometric titrations in the presence and absence of 40-fold excess of Ca2+. 
The titrations were performed with standardized 0.2 M NaOH. For the experiments 
commercially available gadobutrol (Gadovist, Gd(BT-DO3A); Bayer Schering 
Pharma AG) and gadoteridol (ProHance, Gd(HP-DO3A); Bracco Imaging S.p.a) 
contrast agents were used. The concentration of the Gd(HB-DO3A) stock solution 
was determined as it was described in Ref. 42. 
 
Equilibrium studies: The equilibrium studies were performed similarly as it was 
described in Ref. 3. The protonation constants of Gd(BT-DO3A), Gd(HP-DO3A) and 





37C ([GdL] = 0.002 M). For the calibration of pH-meter at 25C and 37C, 0.05 M 
KH-phthalate (pH = 4.005 and 4.028 at 25 C and 37 C) and 0.01 M borax (pH = 
9.177 and 9.081 at 25 C and 37 C) buffers were used.43 To calculate the H+ 
concentration from the measured pH values, the method proposed by Irving et al. was 
used.44 The ionization constant of water at 25C and 37C in 0.15 M NaCl was found 
to be 13.81 and 13.40, which agrees with the published value (pKw=13.85 and 13.38 
at 25C and 37C).37,45 The protonation constants of Gd(BT-DO3A), Gd(HP-DO3A) 
and Gd(HB-DO3A) complexes were calculated by the PSEQUAD program.46 The 




The interactions between Type I Collagen from bovine Achilles tendon (Sigma Aldrich) 
and the macrocyclic GdIII complexes (gadoterate meglumine, gadobutrol, gadoteridol 
and Gd(HB-DO3A)) were studied at pH = 7.4 and 37 C in 1.0 mM Na2HPO4 and 0.15 
M NaCl solution. Commercially available gadoterate meglumine (Dotarem, 
Gd(DOTA); Guerbet) was used, in addition to other already described compounds. In 
these experiments, 48150 mg dry collagen was suspended in 2 mL buffer solution 
(pH = 7.4, 1.0 mM Na2HPO4, 0.15 M NaCl) spiked with 0, 0.5, 1.0, 2.0, 3,0, 4.0, 5.0 
and 7.0 mM macrocyclic GdIII complexes. Before preparing the suspension, the pH of 
the buffer was adjusted to 7.4 by addition of concentrated HCl or NaOH solution. The 
suspensions were stirred for 4 h at 37C in a closed vial. Then, the samples were 
filtered in Amicon® Ultra-4 10K centrifugal filter devices at 37C and 3000 rpm for 30 
s, to obtain about 30 L solution with low molecular weight (< 10 kD) components. 
Our preliminary experiments confirmed that the separation of 30 L solution from the 
suspensions by the use of a short filtration time (30 s) does not influence the chemical 
equilibria reached between type I collagen and the macrocyclic GdIII-complexes. 
Micellar Electrokinetic Capillary Chromatography (MEKC, see below) was used to 
determine the amount of the macrocyclic GdIII-complexes in the buffer solution and in 
the samples obtained by ultrafiltration, allowing to obtain the amount of the GdIII 






Micellar Electrokinetic Capillary Chromatography (MEKC) was successfully used for 
the separation and determination of the macrocyclic GBCAs in serum and urine 
samples.48 A Hewlett-Packard HP3D capillary electrophoresis system was used and 
separations were performed using bare fused-silica capillaries of 56 cm x 50 μm i.d. 
(Agilent). Before use, the capillaries were washed with 1.0 M NaOH (15 min), 0.1 M 
NaOH (30 min) and with the buffer electrolyte (30 min). All buffers had been filtered 
through a 0.45 μm syringe filter and stored in refrigerator at +4C. Samples were 
injected hydrodynamically at the anodic end of the capillary (50 mbar, 20 s). The 
capillary was preconditioned with the buffer electrolyte (25 mM Na2HPO4, 70 mM 
sodium dodecyl sulphate-SDS, pH = 9.1) for 3 min. The separation was performed at 
12C with the application of 20 kV voltage. After analysis, postconditioning with 0.1 M 
NaOH (3 min) and buffer (3 min) was applied to remove all possibly adsorbed 
materials from the capillary. In all measurements, 5 mM DMSO as internal standard 
was applied in order to correct the migration time of components on the 
electropherogram. Detection was carried out by on-column DAD measurement at 200 
nm. The electropherograms were recorded and processed by a ChemStation (Agilent 
- B.04.02 version). Some characteristic electropherograms for the determination of 
the macrocyclic GdIII-complexes are shown in Figure 7.9. The individual linear 
regression equations (response-concentration) for each macrocyclic GdIII-complex 
were based on seven concentrations. The peak areas were linear (R2>0.998) in the 
concentration range specified in Table 7.5, in each case with a precision better than 




The interactions between Type I Collagen from bovine Achilles tendon (Sigma Aldrich) 
and the macrocyclic GdIII complexes (gadoterate meglumine, gadobutrol, gadoteridol 
and Gd(HB-DO3A)) were studied by dialysis with the use of cellulose membrane (12 
kD, Sigma Aldrich) at pH = 7.4 and 37 C in 1.0 mM Na2HPO4 and 0.15 M NaCl 





solution as indicated by Sigma Aldrich (50 mM TRIS buffer, 0.36 mM CaCl2, pH 7.4). 
Removal of glycerol included as a humectant of the cellulose membrane was 
accomplished by washing the membrane for 3 – 4 h at pH = 7.4 and 37 C in 1.0 mM 
Na2HPO4 and 0.15 M NaCl solution. In the dialysis experiments 6.52.3 cm 
membranes with the collagen suspension (150 mg dry collagen) were dialysed in 
500 mL buffer solution in the presence and absence of macrocyclic GdIII complexes. 
Before the dialysis, the membranes with the collagen suspension were equilibrated 
for 4 h at pH = 7.4 and 37 C in 1.0 mM Na2HPO4 and 0.15 M NaCl solution.  
The adsorption rate of macrocyclic GdIII complexes was studied by the dialysis of 7 
membranes with about 150 mg collagen suspension at pH = 7.4 and 37 C in 1.0 mM 
Na2HPO4 and 0.15 M NaCl solution in the presence of 1.0 mM gadoterate meglumine, 
gadobutrol, gadoteridol and Gd(HB-DO3A). Membranes with the collagen suspension 
were removed from the buffer solution 5, 10, 30, 60, 120, 180 and 240 min after the 
start of the dialysis.  
In order to determine the effect of membrane on the adsorption rate of macrocyclic 
GdIII complexes, the dialysis of 53 membranes containing 1, 2 and 3 mL buffer (1.0 
mM Na2HPO4 and 0.15 M NaCl solution, pH = 7.4) was performed at pH = 7.4 and 37 
C in 1.0 mM Na2HPO4 and 0.15 M NaCl solution in the presence of 1.0 mM 
gadoterate meglumine, gadobutrol, gadoteridol and Gd(HB-DO3A). Membranes with 
the buffer were removed from the solution 5, 10, 30, 60 and 120 min after the start of 
the dialysis. 
The desorption rate of macrocyclic GdIII complexes was studied by dialysis of 7 
membranes with about 150 mg collagen suspension at pH = 7.4 and 37C in 1.0 mM 
Na2HPO4 and 0.15 M NaCl solution after the equilibration for 4 h at pH = 7.4 and 37C 
in 1.0 mM Na2HPO4 and 0.15 M NaCl solution in the presence of 1.0 mM gadoterate 
meglumine, gadobutrol, gadoteridol and Gd(HB-DO3A). Membranes with the collagen 
suspension were removed from the buffer solution 5, 10, 30, 60, 120, 180 and 240 
min after the start of the dialysis.  
In order to calculate the volume of the dialysed collagen suspension, the density of 





After the dialysis experiment, the collagen suspension was removed from the 
membrane and filtered on a Büchner funnel with filter paper in order to remove the 
buffer solution (filtration time did not affect the amount of GdIII complex adsorbed by 
collagen). Collagen samples were then dried at 105C overnight. The Gd3+ content of 
collagen samples and buffer solutions was determined by ICP-OES after atmospheric 
remineralisation carried out 4 times by addition of 30% H2O2 and 65% HNO3 solutions.   
 
ICP-OES measurements 
Inductively Coupled Plasma-Optical Emission Spectrometry analysis of gadolinium 
content was performed on an OPTIMA 2100 DV Perkin Elmer spectrophotometer. 
Instrumental parameters of ICP-OES are shown in Table 7.4. 
 
Nebulizer gas flow 0.6 L/min 
Argon auxiliary gas flow 0.2 L/min 
Argon plasma gas flow 15 L/min 
Air pressure (shear gas) 7 bar 
Nitrogen pressure 5 bar 
Argon pressure 7.5 bar 
RF power 1400 W 
Pump flow rate 1.5 mL/min 
Table 7.4. Instrumental parameters setting for the measurements. 
 
Quantification was carried out focusing on 376.839 nm wavelength of gadolinium in 
axial view, using rhodium 1 mg/L (wavelength 343.489 nm) as internal standard. 
Samples resulting from dialysis experiments were properly diluted in 2% HNO3 and 
then analyzed by ICP-OES.  
Calibration blanks, calibration standards, and control standard solutions for the 
analytical sequence were prepared in 2% HNO3 by dilution of a gadolinium oxide 
(Gd2O3) standard solution (1000 mg/L in 2% HNO3, Certipur, Merck). Linearity of the 





concentration in the range of 10 - 1000 µg/L. The correlation between signal intensities 
and concentration was found to be linear with a coefficient of determination R2 > 
0.999. The limit of quantification was set to the first point of the calibration curve (10 
µg/L) and verified considering the signal-to-noise ratio (S/N > 60). 
 
Conclusions 
These studies reveal that macrocyclic GBCAs interact differently with collagen. 
Gadoterate meglumine may form an electrostatic interaction with collagen, whereas 
weak electrostatic interactions and concurrent hydrogen-bonds may be formed 
between gadobutrol and collagen. The weaker interactions of collagen with 
gadoteridol and Gd(HB-DO3A) may be explained by the presence of hydrophobic 
methyl and ethyl groups and the more basic -OH groups (the formation of GdLH-1 
species occurs at more elevated pH). Although these data are based on a simplified 
in vitro model, subtle differences in molecular structure seem to cause measurable 
differences in the interaction of macrocyclic GBCAs with type I collagen, which may 
explain in part the mechanisms that govern the ultimate retention of gadolinium in 
living systems. Indeed, the reported results are compatible with experimental data 
collected in rats, which reveal lower levels of retained gadolinium in soft tissues for 








Acid-base properties of Gd(BT-DO3A), Gd(HP-
DO3A) and Gd(HB-DO3A) complexes at 37C in 
0.15 M NaCl solution. 
The distributions of GdL and GdLH-1 species formed by Gd(BT-DO3A), Gd(HP-DO3A) 
and Gd(BT-DO3A) as a function of pH are shown Figures 7.6 – 7.8. 
 
 
Figure 7.6. Distribution of [Gd(BT-DO3A] – [Gd(BT-DO3A)H-1] species as a function 







Figure 7.7. Distribution of [Gd(HP-DO3A] – [Gd(HP-DO3A)H-1] species as a function 
of pH ([Gd(HP-DO3A)] = 0.001 M, 37 C, 0.15 M NaCl). 
 
 
Figure 7.8. Distribution of [Gd(HB-DO3A] – [Gd(HB-DO3A)H-1] species as a function 





The data presented in Table 7.5 demonstrate that the deprotonation of the alcoholic 
-OH group proceeds at much lower pH values for Gd(BT-DO3A) than for Gd(HP-
DO3A) or Gd(HB-DO3A). Based on the species distribution, the deprotonation of the 
alcoholic –OH group of Gd(BT-DO3A) complex takes place via the formation of 
Gd(BT-DO3A)H-1 species (5.7 %) at physiological conditions (pH = 7.4, 37 C, 0.15 M 
NaCl). Conversely, the acidity of the –OH proton of the Gd(HP-DO3A) and Gd(HB-
DO3A) complexes is significantly lower and results in the formation of Gd(HP-
DO3A)H-1 and Gd(HB-DO3A)H-1 species only at pH > 9 in both cases, therefore 




Figure 7.9. MEKC electropherograms of gadoterate meglumine (A), gadobutrol (B), 
gadoteridol (C) and Gd(HB-DO3A) (D) (Samples: [GdL] = 1.0, 2.0, 3.0 and 4.0 mM, 
pH = 7.4, 1.0 mM Na2HPO4 0.15 M NaCl, 5.0 mM DMSO, Conditions: 20 kV, 50 mbar 






 molar integral 
(mAu/M) 
LODa (M) Linear range (M) 
gadoterate meglumine (9.90.3)104 6.7  
 
5.010-4 – 7.010-3 
gadobutrol (7.50.1)104 5.8 
gadoteridol (6.20.1)104 7.0 
Gd(HB-DO3A) (8.30.1)104 6.2 
Table 7.5. Analytical performance data of MEKC determination of gadoterate 
meglumine, gadobutrol, gadoteridol and Gd(HB-DO3A). a LOD = 3/molar integral. 
 
Diffusion of the macrocyclic GdIII-complexes in 
the absence of collagen 
In order to determine the effect of the membrane on the adsorption and desorption of 
macrocyclic GdIII complexes on/from collagen, dialysis of 5 membranes with 1, 2 and 
3 mL solutions (wash in: 1.0 mM Na2HPO4, 0.15 M NaCl, pH = 7.4; wash out: 1.0 mM 
GdIII-complex, 1.0 mM Na2HPO4, 0.15 M NaCl, pH = 7.4) was performed in 500 mL 
buffer (pH = 7.4 and 37C in 1.0 mM Na2HPO4 and 0.15 M NaCl) in the presence 
(wash in) and absence (wash out) of 1.0 mM gadoterate meglumine, gadobutrol, 
gadoteridol or Gd(HB-DO3A). Rates of the wash-in and wash-out processes 
(Equation 7.3) were obtained by the ICP-OES determination of the macrocyclic GdIII 
complexes in the solutions within the membranes: 
                                                    GdLbuffer  GdLmembrane                                                  (7.3) 
where GdLbuffer and GdLmembrane are the macrocyclic GdIII complexes in the buffer and 
in the membrane, respectively. The amounts of the GdIII complexes in the membranes 







Figure 7.10. Amounts of GdIII complexes in the membrane as a function of time (wash 
in). (gadoterate meglumine (A), gadobutrol (B), gadoteridol (C) and Gd(HB-DO3A) 
(D), 1 mL (◆), 2 mL (◼) and 3 mL (), buffer: [GdL] = 1.0 mM, pH = 7.4, 37 C, 1.0 
mM. Na2HPO4, 0.15 M NaCl) Symbols and solid lines represent the experimental and 
the calculated [GdL] values, respectively. 
 
 
Figure 7.11. Amounts of GdIII complexes in the membrane as a function of time (wash 
out). (gadoterate meglumine (A), gadobutrol (B), gadoteridol (C) and Gd(HB-DO3A) 
(D), 1 mL (◆), 2 mL (◼) and 3 mL (), buffer: pH = 7.4, 37C, 1.0 mM Na2HPO4, 0.15 






In the presence (wash-in) and absence (wash-out) of GdL excess in the buffer solution 
(500 mL), the wash-in and the wash-out can be treated as a pseudo-first-order 
process and the rate can be expressed with the Equation 7.4 and Equation 7.5, 
where kobs is a pseudo-first-order rate constant and [GdL]t is the total concentration of 
the macrocyclic GdIII complex in the buffer (wash-in) and in the membrane (wash-out). 
 
                                      (7.4) 
 
                                                                            (7.5) 
 
The rate constants (kobs) characterizing the wash-in and wash-out of GdIII complexes 





where [GdL]0, [GdL] and [GdL] are the concentrations of GdL complex at the start, 
the end and at the time t of the reaction. The kobs rate constants are shown in Table 






















Wash-IN Dotarem Gadovist ProHance Gd(HB-DO3A) 
kobs/min-1 
(1 mL) 
0.022  0.001 0.026  0.003 0.030  0.004 0.016  0.001 
kobs /min-
1
 (2 mL) 
0.014  0.001 0.016  0.001 0.018  0.002 0.009  0.0003 
kobs /min-1 
(3 mL) 









(6.4  0.4)10-4 
Wash-
OUT 
Dotarem Gadovist ProHance Gd(HB-DO3A) 
kobs/min-1 
(1 mL) 
0.024  0.002 0.027  0.004 0.026  0.004 0.018  0.001 
kobs/min-1 
(2 mL) 
0.014  0.001 0.014  0.001 0.014  0.003 0.010  0.001 
kobs/min-1 
(3 mL) 









(6.0  0.3)10-4 
Table 7.6. Rate constant characterizing the wash-in and wash-out of macrocyclic 
GdIII-complexes (buffer: [GdL]t=1.0 mM (wash in), 0.0 mM (wash out), pH=7.4, 37C, 
1.0 mM Na2HPO4, 0.15 M NaCl). 
 
The kobs rate constants characterizing the wash-in and wash-out process of 
gadoterate meglumine, gadobutrol and gadoteridol in the presence of 1.0 mM GdIII 
complexes in the buffer (wash-in) and in the membrane (wash-out) are essentially 
identical and decrease with the increase of the volume in the membrane. However, 
the kobs values of Gd(HB-DO3A) are somewhat lower than those of other complexes, 
which might be explained by the more hydrophobic character of the 2-hydroxy-butyl 
sidechain that results in the slower wash-in and wash-out processes of Gd(HB-DO3A) 





of molecules and to the ratio of membrane surface area to membrane volume (specific 
surface of the membrane).34 Since the wash-in and wash-out experiments were 
performed in the presence of 1.0 mM GdIII complex in the buffer (wash-in) and in the 
membrane (wash-out), the kobs can be expressed by the following equation: 
 
                                       (7.7) 
 
where kin/out is the rate constant characterizing the diffusion of the GdIII complexes in 
the presence of 1.0 mM GdIII complex in the buffer (wash-in) and in the membrane 
(wash-out). Considering the surface area of the membrane (26.52.3=29.9 cm2) and 
the volume of the buffer (1, 2 and 3 mL) in the membrane, kin and kout rate constants 
characterizing the permeability of the membrane for the GdIII complexes were 
calculated in the presence of 1.0 mM GdIII complex in the buffer (wash-in) or in the 
membrane (wash-out) (Table S4). kin and kout rate constants characterizing the 
diffusion of the gadoterate meglumine, gadobutrol and gadoteridol in the presence of 
1.0 mM GdIII complex in the buffer (wash-in) and in the membrane (wash-out) are 
essentially identical, which reveals that the cellulose membrane (12 kD, Sigma 
Aldrich) has practically no influence on the rate of the adsorption and desorption of 









The distribution, adsorption/desorption and 




Figure 7.12. The distribution, adsorption and elimination of gadoterate meglumine 
(A), gadovist (B), gadoteridol (C) and Gd(HB-DO3A) (D) Amounts of GdL in the 
plasma (1), in the interstitium (2), the eliminated GdL (3) and the adsorbed GdL by 
collagen (4). The distribution volume was 0.25 L/kg body weight, the weight of total 
collagen was 2.65 kg, the volume of the plasma was taken 3.5 L and the dose of CA 
was 0.1 mmol/kg body weight for a 70 kg patient. 
 
T (hours) gadoterate meglumine gadobutrol gadoteridol Gd(HB-DO3A) 
24 85.251 82.898 85.266 85.283 
48 97.832 97.084 97.834 97.837 
168 100.000 99.999 100.000 100.000 
720 100.000 100.000 100.000 100.000 
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For this work, I have prepared and characterised HB-DO3A(tBu)3 and HB-DO3A and 

























As thoroughly explained in the previous pages, during my PhD the utmost attention 
was paid to the improved synthesis of chelating agents with the aim of preparing novel 
contrast agents primarily for MRI, PET and SPECT. 
This interest derives from an open research issue, since chemical industries 
producing CAs have a continuous need for new synthetic strategies and more 
complex compounds possessing refined profiles of safety, efficacy and cost. 
Currently, polyazamacrocyclic polycarboxylate and phosphonates complexes, 
represent the best combination of performances and in vivo stability when used as 
imaging contrast agents and drugs for targeted radiotherapy.1 Nevertheless, the 
synthesis of functionalised polyazamacrocycles is not straightforward and requires 
simple and efficient regioselective protection methods.2  
Therefore, as stated in Chapter 2, my PhD has been focused on three main 
objectives: 
• Regioselective protection of cyclen, 
• Synthesis of novel bifunctional chelating agents, 
• Synthesis of new chelating agents. 
The first project was developed designing a strategy for the orthogonal 1,7 
diprotection of cyclen. The latter is an important starting material since it represents 
the basic skeleton of several complexes used as CAs (mainly for MRI, PET, SPECT 
and OI). The functionalization of this macrocycle often requires complex strategies of 
protection and deprotection. The presence of four symmetrically arranged nitrogen 
atoms makes possible a series of protected derivatives, summarized in Figure 8.1.3 
 
 
Figure 8.1. Cyclen, protected derivatives (PG = Protective Group). 
 
A novel strategy for the preparation of orthogonally 1,7-heterodiprotected cyclen-





inexpensive reagents, and mild conditions. Our method is inspired by a protocol 
developed by A. D. Sherry et al.,4 and based on the control of pH to modulate the 
reactivity of the equivalent amine groups. The original method is based on the peculiar 
behaviour of polyazamacrocycles, i.e. the fact that the protonation of amino groups is 
sequential, and the first two protonation steps occur on opposite nitrogen atoms due 
to electrostatic repulsion of the incoming positive charges. This property allows to 
operate on the diprotonated cyclen and can be exploited to implant protective groups 
with an high 1,7 regioselectivity. This property allows the functionalisation of cyclen 
with two different side arms (A2B2 arrangement). The protocol developed during my 
PhD, instead, allows the functionalisation of cyclen with three different side arms 
(A2BC arrangement), widening the chemical space of multifunctionalised cyclens and 
improving its chelating properties. (Figure 8.2)  
 
 
Figure 8.2. Strategies for the 1,7-protection of cyclen. 
 
Our protocol starts from a monoprotected cyclen, the N-formylderivative, easily 
available in large amount following a published procedure.5 Products and isolated 







Figure 8.3. Scheme of the products and corresponding isolated yields. 
 
The advantages of this method are: 
1. The protecting groups are easily removed under mild conditions and are 
orthogonal to each other (they can be selectively and independently cleaved 
leaving the other group intact), 
2. This protocol gives an efficient and alternative entry to Cbz and BOC 
monoprotected cyclens, 
3. This method does not require chromatographic separation or high dilution 
techniques, 
4. The final compounds are easily obtained with good yields (Figure 8.3). 
Future developments of this topic will be devoted to the realization of 1,4-diprotected 
derivatives of cyclen. 
 
The second topic of my PhD was focused on the design and synthesis of two novel 
BFCAs (DO2AP(tBu)4 and DO3AP(tBu)4) as derivatives of DO3AP. (Figure 8.4) 
The phosphonic group is commonly used as a (bio)isostere of carboxylic acid in 
medicinal chemistry.6 At physiological pH values the phosphonate deprotonated form 
(-PO32-) offers multiple coordination modes, leading to stabilities of the metal 
complexes comparable to those of the carboxylic counterpart or even higher.1,7,8 
(Figure 8.4)  
This feature is very important for the application of a BFCA as drug for targeted 
radiotherapy or imaging probes. Moreover, the anions left after complexation on the 
phosphonate group provide an extended and beneficial hydrogen bond network. This 
property gives paramagnetic complexes an improved relaxivity (i.e.: contrast 






Figure 8.4. DOTA and DO3AP. 
 
For these reasons, during my PhD I have prepared two new bifunctional chelating 
agents, derivatives of DO3AP, i.e.: DO2AP(tBu)4 and DO3AP(tBu)4 (Figure 8.5), 
prepared by a straightforward and economic synthetic access. 
 
 
Figure 8.5. DO2AP(tBu)4 and DO3AP(tBu)4. 
 
The synthesis of these BFCA derivatives takes advantage of the orthogonally 1,7-
heterodiprotected cyclen derivatives showed in the previous section, precisely of 1-
Cbz-7-formyl derivative of cyclen. 
The secondary amino group of DO2AP(tBu)4 is the reactive functional group of this 
novel BFCA and can be used to link the coordinating cage to suitable vectors by 
simple alkyation of the nitrogen atom.  
In DO3AP(tBu)4, instead, the free carboxylic group is the key functionality that can be 
activated and coupled to vector-molecules. 
Future developments will concern the conjugation of the BFCAs presented here to 





Regarding the third issue of my PhD, the research was focused on the design and 
preparation of three innovative chelating agents (TRASUTA, cb-tebpm and HB-
DO3A) and metal complexes thereof.  
TRASUTA consists of a new hexadentate mesocyclic chelating agent for gallium as 
a derivative of AAZTA for application as a PET CA.  
In particular, TRASUTA consist in a rigidified derivative of AAZTA, bearing, on its 
mesocyclic structure a newly introduced five-membered cycle. (Figure 8.6) 
 
 
Figure 8.6. TRASUTA consist in a rigidified hexadentate analogue of AAZTA rigidified 
by the introduction of a new five-membered cycle (highlighted in green). 
 
TRASUTA has been synthesised in seven steps using, as starting materials, 
commercial and cheap products. The stability constant of Ga3+-TRASUTA have been 
measured by potentiometric titration and the corresponding data are reported in 
Chapter 5.  
Future developments of this project will concern the improvement of the synthesis 
of TRASUTA, with a special focus on the reaction conditions and their influence on 
the overall yield. 
 
Cb-tebpm is another novel chelating agent prepared during this PhD and designed 









Figure 8.7. Cb-tebpm and [Gd(cb-tebpm)]. 
 
In the recent literature has been reported that cross-bridged cyclams (such as cb-
tebpm) form metal complexes with great kinetic inertness, very important for their 
application as MRI CAs.9  
 
Cb-tebpm has been prepared by a two-step synthesis (three steps for its gadolinium 
complex).  
Preliminary complexometric experiments revealed that [Gd(cb-tebpm)] shows a 
kinetic inertness comparable or even higher than other cyclam derivativatives 
previously reported in the literature even in strongly dissociating conditions (i.e. strong 
acidic media).  
This synthetic access presents the great advantage of avoiding the use of protecting 
groups, shortening the preparation of cb-tebpm.  
Future development of this project will concern the optimization of the reaction 
condition, yields and purification procedure with the perspective of a possible future 
scale up of the synthesis of cb-tebpm.  
Moreover, we will study of the complexation properties of cb-tebpm with other 
lanthanides and transition metals.  
 
HB-DO3A has been the last innovative chelating agent designed and prepared during 
my PhD. Its gadolinium complex has been studied from a complexometric, 
pharmacokinetic and toxicological point of view. These experiments were devoted to 







gadoteridol and gadobutrol) and Gd(HB-DO3A) in their interaction with type I 
collagen. (Figure 8.8) The latter is one of the most important components of interstitial 
fluids10 and the interaction of the previously mentioned gadolinium complexes with 
collagen has never been thoroughly studied.  
 
 
Figure 8.8. Structures of macrocyclic ligands gadoterate meglumine, gadoteridol 
gadobutrol and Gd(HB-DO3A). 
 
HB-DO3A was prepared in two easy synthetic steps and purification procedures in 
high isolated yield (75 % over two steps) on a multigram scale.  
Ex vivo experiments have demonstrated that owing to their different chemical 
structure, gadoterate meglumine, gadoteridol, gadobutrol and Gd(HB-DO3A) present 
different affinity to collagen and therefore different pharmacokinetic profiles.  
In fact, the net negative charge of gadoterate and the partial negative charge and the 
OH groups of gadobutrol allow stronger ionic and hydrogen bonds to the positively 
charged and highly hydrated collagen molecules. Neutral gadoteridol and Gd(HB-
DO3A) interact less efficiently with collagen, and affinity decreases as lipophilicity 
(and therefore the length of the side chain bearing the OH) increases. 
The lower affinity to collagen can be reflected in a lower accumulation in the body 
after administration, in a faster and complete clearance and therefore fewer side 
effects related to the deposit of free gadolinium in the organism.  
The insight provided by this work could represent an actual step forward for the 
treatment of patients which need repeated contrast enhanced MRI scans to follow the 







In fact, these patients and those with chronic conditions, such as renal failure, are 
particularly sensitive to the administration of gadolinium-based CAs which are 
sometimes indispensable for them.  
These patients tend to accumulate more than others free gadolinium ions, which can 
lead to toxic effect in an already compromised organism.11 
Therefore, in particular for these patients a careful evaluation of the gadolinium-based 
MRI CA to be administered is necessary to prevent aggravation of pre-existing 
diseases. 
Future developments of this work will concern the validation of the thesis presented 
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